Pharsight

1. Abilify Mycite Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11229378	OTSUKA	Communication system with enhanced partial power source and method of manufacturing same	Jul, 2031 (7 years from now)
US9320455	OTSUKA	Highly reliable ingestible event markers and methods for using the same	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-150)	Dec 05, 2017
New Indication(I-746)	Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
30MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription

ABILIFY MYCITE KIT family patents

2. Accrufer patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248148	SHIELD TX	Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 25, 2024

Drugs and Companies using FERRIC MALTOL ingredient

NCE-1 date: 26 July, 2023

Market Authorisation Date: 25 July, 2019

Treatment: Method of treating iron deficiency

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
30MG IRON	CAPSULE;ORAL	Prescription

ACCRUFER family patents

3. Acetadote patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9327028	CUMBERLAND PHARMS	Acetylcysteine compositions and methods of use thereof	Jul, 2031 (7 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 mg/mL, 30 mL vials	04 Apr, 2012	3	07 Nov, 2012	21 May, 2026	Eligible

Strength	Dosage	Availability
6GM/30ML (200MG/ML)	INJECTABLE;INTRAVENOUS	Prescription

ACETADOTE family patents

4. Adlyxin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8882721	SANOFI-AVENTIS US	Drive assembly suitable for use in a drug delivery device and drug delivery device	Jun, 2031 (7 years from now)
US9084853	SANOFI-AVENTIS US	Drive mechanism for a drug delivery device and drug delivery device	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 27, 2021

Drugs and Companies using LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 27 July, 2016

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
0.15MG/3ML (0.05MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription
0.3MG/3ML (0.1MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

ADLYXIN family patents

5. Afrezza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358352	MANNKIND	Dry powder drug delivery system and methods	Feb, 2031 (6 years from now)
US8227409	MANNKIND	Diketopiperazine microparticles with defined isomer contents	Mar, 2031 (6 years from now)
US9597374	MANNKIND	Use of ultrarapid acting insulin	Oct, 2031 (7 years from now)
US8424518	MANNKIND	Dry powder inhaler and system for drug delivery	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 27, 2017

Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient

Market Authorisation Date: 27 June, 2014

Treatment: Use of an inhaler to administer dry powder medicament; Administration of fdkp microparticles comprising insulin.; Method of controlling glycemia in diabetics by administering an initial dose of insuli...

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
4 UNITS/INH	POWDER;INHALATION	Prescription
8 UNITS/INH	POWDER;INHALATION	Prescription
12 UNITS/INH	POWDER;INHALATION	Prescription

AFREZZA family patents

6. Airduo Digihaler patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Feb, 2031 (6 years from now)
US9731087	TEVA PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US10124131	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10022510	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US9216260	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jun, 2031 (7 years from now)
US10195375 (Pediatric)	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Aug, 2031 (7 years from now)
US9731087 (Pediatric)	TEVA PHARM	Dose counter for inhaler having a bore and shaft arrangement	Nov, 2031 (7 years from now)
US10022510 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Nov, 2031 (7 years from now)
US10124131 (Pediatric)	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Nov, 2031 (7 years from now)
US9216260 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-61)	Jul 09, 2024
Pediatric Exclusivity(PED)	Jan 09, 2025
New Product(NP)	Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

AIRDUO DIGIHALER family patents

7. Airduo Respiclick patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Feb, 2031 (6 years from now)
US9731087	TEVA PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US10124131	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10022510	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US9216260	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jun, 2031 (7 years from now)
US10195375 (Pediatric)	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Aug, 2031 (7 years from now)
US10022510 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Nov, 2031 (7 years from now)
US9731087 (Pediatric)	TEVA PHARM	Dose counter for inhaler having a bore and shaft arrangement	Nov, 2031 (7 years from now)
US10124131 (Pediatric)	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Nov, 2031 (7 years from now)
US9216260 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-61)	Jul 09, 2024
Pediatric Exclusivity(PED)	Jan 09, 2025
New Product(NP)	Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

AIRDUO RESPICLICK family patents

8. Akeega patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP04743564A	2012-04-13	STRAWMAN LIMITED	Patent maintained as amended
EP04743564A	2012-04-13	Adams, Harvey Vaughan John	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8859562	October, 2011	Decision	Thomas Helleday

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8071623	JANSSEN BIOTECH	Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors	Mar, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859562	JANSSEN BIOTECH	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET;ORAL

Strength	Dosage	Availability
500MG;EQ 100MG BASE	TABLET;ORAL	Prescription
500MG;EQ 50MG BASE	TABLET;ORAL	Prescription

AKEEGA family patents

9. Aklief patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7807708	GALDERMA LABS LP	Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 04, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 05 October, 2023

Market Authorisation Date: 04 October, 2019

Treatment: NA

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
0.005%	CREAM;TOPICAL	Prescription

AKLIEF family patents

10. Akynzeo patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP14151676A	2016-07-20	Teva Pharmaceutical Industries Ltd	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9271975	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 10, 2019

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 10 October, 2018

Market Authorisation Date: 10 October, 2014

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limite...

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
300MG;EQ 0.5MG BASE	CAPSULE;ORAL	Prescription

AKYNZEO family patents

11. Alecensa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9126931	HOFFMANN-LA ROCHE	Tetracyclic compound	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-159)	Nov 06, 2024
New Indication(I-756)	Nov 06, 2020
Orphan Drug Exclusivity(ODE-105)	Dec 11, 2022
Orphan Drug Exclusivity(ODE)	Nov 06, 2024
New Chemical Entity Exclusivity(NCE)	Dec 11, 2020

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

NCE-1 date: 12 December, 2019

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
150 mg	11 Dec, 2019	1		04 Mar, 2032

Strength	Dosage	Availability
EQ 150MG BASE	CAPSULE;ORAL	Prescription

ALECENSA family patents

12. Alunbrig patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP09751617A	2018-06-05	Generics (UK) Ltd	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9012462	TAKEDA PHARMS USA	Phosphorous derivatives as kinase inhibitors	Apr, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-142)	Apr 28, 2024
Orphan Drug Exclusivity(ODE-300)	May 22, 2027
New Chemical Entity Exclusivity(NCE)	Apr 28, 2022
Orphan Drug Exclusivity(ODE)	Apr 28, 2024
New Indication(I-847)	May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
30MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription
180MG	TABLET;ORAL	Prescription

ALUNBRIG family patents

13. Angeliq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8906890	BAYER HLTHCARE	Very low-dosed solid oral dosage forms for HRT	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Strength(NS)	Mar 01, 2015

Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient

Market Authorisation Date: 29 February, 2012

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.5 mg/1 mg	26 Dec, 2007	1		11 Aug, 2017	Extinguished
0.25 mg/0.5 mg	08 Jan, 2015	1		22 Oct, 2031	Extinguished

Strength	Dosage	Availability
0.25MG;0.5MG	TABLET;ORAL	Prescription

ANGELIQ family patents

14. Anoro Ellipta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8746242 (Pediatric)	GLAXOSMITHKLINE	Medicament dispenser	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 18, 2016
New Chemical Entity Exclusivity(NCE)	Dec 18, 2018
M(M-245)	Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

ANORO ELLIPTA family patents

15. Apadaz patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8461137	ZEVRA THERAP	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Feb, 2031 (6 years from now)

Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 January, 2019

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
325MG;EQ 8.16MG BASE	TABLET;ORAL	Discontinued
325MG;EQ 6.12MG BASE	TABLET;ORAL	Discontinued
325MG;EQ 4.08MG BASE	TABLET;ORAL	Discontinued

APADAZ family patents

16. Apretude patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597	VIIV HLTHCARE	Pharmaceutical compositions	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 20 December, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

APRETUDE family patents

17. Armonair Digihaler patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Feb, 2031 (6 years from now)
US8714149 (Pediatric)	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	May, 2031 (7 years from now)
US10124131	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US9731087	TEVA PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US10022510	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US9216260	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jun, 2031 (7 years from now)
US10195375 (Pediatric)	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Aug, 2031 (7 years from now)
US9731087 (Pediatric)	TEVA PHARM	Dose counter for inhaler having a bore and shaft arrangement	Nov, 2031 (7 years from now)
US10124131 (Pediatric)	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Nov, 2031 (7 years from now)
US10022510 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Nov, 2031 (7 years from now)
US9216260 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jul 09, 2024
New Strength(NS)	Jul 09, 2024
Pediatric Exclusivity(PED)	Jan 09, 2025
New Product(NP)	Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER;INHALATION

ARMONAIR DIGIHALER family patents

18. Armonair Respiclick patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195375	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Feb, 2031 (6 years from now)
US9731087	TEVA PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US10022510	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US10124131	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US9216260	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jun, 2031 (7 years from now)
US10195375 (Pediatric)	TEVA PHARM	Airflow adaptor for a breath-actuated dry powder inhaler	Aug, 2031 (7 years from now)
US10022510 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Nov, 2031 (7 years from now)
US9731087 (Pediatric)	TEVA PHARM	Dose counter for inhaler having a bore and shaft arrangement	Nov, 2031 (7 years from now)
US10124131 (Pediatric)	TEVA PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	Nov, 2031 (7 years from now)
US9216260 (Pediatric)	TEVA PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jul 09, 2024
New Strength(NS)	Jul 09, 2024
Pediatric Exclusivity(PED)	Jan 09, 2025
New Product(NP)	Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER;INHALATION

ARMONAIR RESPICLICK family patents

19. Arnuity Ellipta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8746242 (Pediatric)	GLAXOSMITHKLINE	Medicament dispenser	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-290)	Mar 01, 2026
New Strength(NS)	May 17, 2021
New Patient Population(NPP)	May 17, 2021
New Product(NP)	Aug 20, 2017

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 17 May, 2018

Treatment: NA

Dosage: POWDER;INHALATION

ARNUITY ELLIPTA family patents

20. Aubagio patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735 (Pediatric)	SANOFI AVENTIS US	(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-61)	Apr 30, 2024
Pediatric Exclusivity(PED)	Oct 30, 2024
New Chemical Entity Exclusivity(NCE)	Sep 12, 2017

Drugs and Companies using TERIFLUNOMIDE ingredient

NCE-1 date: 31 October, 2023

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

AUBAGIO family patents

21. Austedo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733	TEVA BRANDED PHARM	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Apr, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733 (Pediatric)	TEVA BRANDED PHARM	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-134)	Apr 03, 2024
M(M-54)	Jun 24, 2024
Pediatric Exclusivity(PED)	Dec 24, 2024
New Indication(I-751)	Aug 30, 2020
New Chemical Entity Exclusivity(NCE)	Apr 03, 2022
Orphan Drug Exclusivity(ODE)	Apr 03, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: 25 December, 2023

Market Authorisation Date: 03 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

AUSTEDO family patents

22. Austedo Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733	TEVA	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Apr, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733 (Pediatric)	TEVA	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Oct, 2031 (7 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 17 February, 2023

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

AUSTEDO XR family patents

23. Avycaz patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8471025	ALLERGAN	Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 25, 2020
New Patient Population(NPP)	Dec 20, 2025
Generating Antibiotic Incentives Now(GAIN)	Feb 25, 2025
New Indication(I-738)	Jun 22, 2019

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 26 February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

AVYCAZ family patents

24. Balversa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071	JANSSEN BIOTECH	Pyrazolyl quinoxaline kinase inhibitors	Apr, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 12, 2024
New Indication(I-930)	Jan 19, 2027

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 13 April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemot...

Dosage: TABLET;ORAL

BALVERSA family patents

25. Barhemsys patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9545426	ACACIA	Use of amisulpride as an anti-emetic	Mar, 2031 (6 years from now)
US10525033	ACACIA	Use of amisulpride as an anti-emetic	Mar, 2031 (6 years from now)
US9889118	ACACIA	Use of amisulpride as an anti-emetic	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: 27 February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Treatment of post-operative nausea and vomiting; Prevention of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

BARHEMSYS family patents

26. Baxdela patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7728143	MELINTA	Salt and crystalline forms thereof of a drug	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 19, 2022
Generating Antibiotic Incentives Now(GAIN)	Jun 19, 2027
New Indication(I-815)	Oct 24, 2022

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS; TABLET;ORAL

BAXDELA family patents

27. Belrapzo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265831	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US10010533	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US11844783	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US11103483	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US9572797	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US9572796	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US8609707	EAGLE PHARMS	Formulations of bendamustine	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
ODE(ODE)	Dec 07, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 May, 2018

Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with chronic lymphocytic leukemia

Dosage: SOLUTION;INTRAVENOUS

BELRAPZO family patents

28. Belviq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770455	EISAI INC	Administration of an anti-obesity compound to individuals with renal impairment	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 27 June, 2012

Treatment: Method for chronic weight management in patients with moderate renal impairment who are obese, or overweight and have at least one weight related comorbid condition

Dosage: TABLET;ORAL

BELVIQ family patents

29. Belviq Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770455	EISAI INC	Administration of an anti-obesity compound to individuals with renal impairment	Aug, 2031 (7 years from now)
US10226471	EISAI INC	Modified-release dosage forms of 5-HT2C agonists useful for weight management	Aug, 2031 (7 years from now)
US10463676	EISAI INC	Modified-release dosage forms of 5-HT2C agonists useful for weight management	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 15 July, 2016

Treatment: Method for chronic weight management in patients with moderate renal impairment who are obese, or overweight and have at least one weight related comorbid condition; Chronic weight management in adult...

Dosage: TABLET, EXTENDED RELEASE;ORAL

BELVIQ XR family patents

30. Bendeka patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10010533	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US11844783	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US9572797	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US9572796	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US11103483	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US9265831	EAGLE PHARMS	Formulations of bendamustine	Jan, 2031 (6 years from now)
US8609707	EAGLE PHARMS	Formulations of bendamustine	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-179)	Dec 07, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2015

Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic ...

Dosage: SOLUTION;IV (INFUSION)

BENDEKA family patents

31. Besivance patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8481526	BAUSCH AND LOMB	Fluoroquinolone carboxylic acid molecular crystals	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 28, 2014

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

NCE-1 date: 28 May, 2013

Market Authorisation Date: 28 May, 2009

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

BESIVANCE family patents

32. Bevespi Aerosphere patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815258	ASTRAZENECA	Compositions, methods and systems for respiratory delivery of two or more active agents	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 25, 2019

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

BEVESPI AEROSPHERE family patents

33. Bevyxxa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8404724	PORTOLA PHARMS INC	Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: 23 June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: Inhibiting coagulation

Dosage: CAPSULE;ORAL

BEVYXXA family patents

34. Binosto patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592195	RADIUS	Stable effervescent bisphosphonate formulations with rapid solubilization characteristics	Dec, 2031 (7 years from now)

Drugs and Companies using ALENDRONATE SODIUM ingredient

Market Authorisation Date: 12 March, 2012

Treatment: NA

Dosage: TABLET, EFFERVESCENT;ORAL

BINOSTO family patents

35. Braftovi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8501758	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Mar, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314464	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-194)	Jun 27, 2025
New Indication(I-928)	Oct 11, 2026
Orphan Drug Exclusivity(ODE-445)	Oct 11, 2030
New Chemical Entity Exclusivity(NCE)	Jun 27, 2023
New Indication(I-826)	Apr 08, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with metastatic non small cell lung cancer with a braf v600e mutation, as detected by an fda-app...

Dosage: CAPSULE;ORAL

BRAFTOVI family patents

36. Brenzavvy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10981942	THERACOSBIO	Crystalline form of benzylbenzene SGLT2 inhibitor	Jun, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10533032	THERACOSBIO	Crystalline form of benzylbenzene SGLT2 inhibitor	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 20 January, 2027

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

BRENZAVVY family patents

37. Breo Ellipta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8746242 (Pediatric)	GLAXO GRP LTD	Medicament dispenser	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	May 13, 2026
New Strength(NS)	May 13, 2026
Pediatric Exclusivity(PED)	Nov 13, 2026
M(M-202)	May 15, 2020
New Product(NP)	May 10, 2016
New Chemical Entity Exclusivity(NCE)	May 10, 2018
New Indication(I-708)	Apr 30, 2018

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 12 May, 2023

Treatment: NA

Dosage: POWDER;INHALATION

BREO ELLIPTA family patents

38. Breztri Aerosphere patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815258	ASTRAZENECA AB	Compositions, methods and systems for respiratory delivery of two or more active agents	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

BREZTRI AEROSPHERE family patents

39. Bryhali patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478502	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)
US11839656	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)
US8809307	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 06, 2021

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 06 November, 2018

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

BRYHALI family patents

40. Bydureon Bcise patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033 (Pediatric)	ASTRAZENECA AB	Sustained release formulations using non-aqueous carriers	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jul 22, 2024
Pediatric Exclusivity(PED)	Jan 22, 2025
M(M-240)	Feb 15, 2022
New Product(NP)	Oct 20, 2020

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON BCISE family patents

41. Byfavo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9827251	ACACIA	Dosing regimen for sedation with CNS 7056 (remimazolam)	Nov, 2031 (7 years from now)
US10195210	ACACIA	Dosing regimen for sedation with CNS 7056 (Remimazolam)	Nov, 2031 (7 years from now)
US10052334	ACACIA	Dosing regimen for sedation with CNS 7056 (remimazolam)	Nov, 2031 (7 years from now)
US10342800	ACACIA	Dosing regimen for sedation with CNS 7056 (Remimazolam)	Nov, 2031 (7 years from now)
US10722522	ACACIA	Dosing regimen for sedation with CNS 7056 (remimazolam)	Nov, 2031 (7 years from now)
US9737547	ACACIA	Dosing regimen for sedation with CNS 7056 (Remimazolam)	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 06, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 06 October, 2024

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

BYFAVO family patents

42. Bylvay patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10981952	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (7 years from now)
US11732006	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (7 years from now)
US9694018	ALBIREO	IBAT inhibitors for the treatment of liver disease	Nov, 2031 (7 years from now)
US10011633	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (7 years from now)
US10487111	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (7 years from now)
US10093697	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 20, 2026
Orphan Drug Exclusivity(ODE-436)	Jun 13, 2030
New Indication(I-918)	Jun 13, 2026
Orphan Drug Exclusivity(ODE-363)	Jul 20, 2028

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 20 July, 2025

Market Authorisation Date: 20 July, 2021

Treatment: Method of reducing serum bile acids in patients 12 months or older suffering from alagille syndrome (algs); Method of treating pruritus in patients 3 months or older suffering from progressive familia...

Dosage: CAPSULE;ORAL; CAPSULE, PELLETS;ORAL

BYLVAY family patents

43. Cabenuva Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597	VIIV HLTHCARE	Pharmaceutical compositions	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 21, 2026
New Patient Population(NPP)	Mar 29, 2025
New Dosing Schedule(D-184)	Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

CABENUVA KIT family patents

44. Cabometyx patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10034873	EXELIXIS INC	C-met modulator pharmaceutical compositions	Jul, 2031 (7 years from now)
US10039757	EXELIXIS INC	C-Met modulator pharmaceutical compositions	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-227)	Jan 14, 2026
New Indication(I-854)	Jan 22, 2024
Orphan Drug Exclusivity(ODE-375)	Sep 17, 2028
New Indication(I-873)	Sep 17, 2024
New Chemical Entity Exclusivity(NCE)	Nov 29, 2017
New Indication(I-760)	Dec 19, 2020
New Product(NP)	Apr 25, 2019
New Indication(I-792)	Jan 14, 2022

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma

Dosage: TABLET;ORAL

CABOMETYX family patents

45. Cerdelga patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888547	GENZYME CORP	Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Aug 19, 2021
New Chemical Entity Exclusivity(NCE)	Aug 19, 2019
Orphan Drug Exclusivity(ODE-73)	Aug 19, 2021

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

NCE-1 date: 19 August, 2018

Market Authorisation Date: 19 August, 2014

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twic...

Dosage: CAPSULE;ORAL

CERDELGA family patents

46. Cleviprex patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8658676	CHIESI	Clevidipine emulsion formulations containing antimicrobial agents	Oct, 2031 (7 years from now)
US11103490	CHIESI	Clevidipine emulsion formulations containing antimicrobial agents	Oct, 2031 (7 years from now)
US10010537	CHIESI	Clevidipine emulsion formulations containing antimicrobial agents	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 01, 2013

Drugs and Companies using CLEVIDIPINE ingredient

NCE-1 date: 01 August, 2012

Market Authorisation Date: 01 August, 2008

Treatment: NA

Dosage: EMULSION;INTRAVENOUS

CLEVIPREX family patents

47. Combogesic Iv patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446266	HIKMA	Combination composition	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 17, 2026

Drugs and Companies using ACETAMINOPHEN; IBUPROFEN SODIUM ingredient

Market Authorisation Date: 17 October, 2023

Treatment: Method of treating moderate to severe pain in adults as an adjunct to opioid analgesics

Dosage: SOLUTION;INTRAVENOUS

COMBOGESIC IV family patents

48. Contrave patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033543	NALPROPION	Methods of providing weight loss therapy in patients with major depression	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

CONTRAVE family patents

49. Cosela patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8598186	G1 THERAP	CDK inhibitors	Oct, 2031 (7 years from now)
US10189849	G1 THERAP	CDK inhibitors	Oct, 2031 (7 years from now)
US8598197	G1 THERAP	CDK inhibitors	Oct, 2031 (7 years from now)
US9957276	G1 THERAP	CDK inhibitors	Oct, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10189850	G1 THERAP	CDK inhibitors	Oct, 2031 (7 years from now)
US10927120	G1 THERAP	CDK inhibitors	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 12 February, 2025

Market Authorisation Date: 12 February, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

COSELA family patents

50. Daklinza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8629171	BRISTOL-MYERS SQUIBB	Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-727)	Feb 05, 2019
New Indication(I-726)	Feb 05, 2019
New Chemical Entity Exclusivity(NCE)	Jul 24, 2020
New Dosing Schedule(D-161)	Feb 05, 2019
New Dosing Schedule(D-162)	Feb 05, 2019

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

NCE-1 date: 25 July, 2019

Market Authorisation Date: 24 July, 2015

Treatment: Method of inhibiting hepatitis c virus

Dosage: TABLET;ORAL

DAKLINZA family patents

51. Daurismo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8148401	PFIZER	Benzimidazole derivatives	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-224)	Nov 21, 2025
New Chemical Entity Exclusivity(NCE)	Nov 21, 2023

Drugs and Companies using GLASDEGIB MALEATE ingredient

NCE-1 date: 21 November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

DAURISMO family patents

52. Dayvigo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8268848	EISAI INC	Cyclopropane compound	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 07, 2025
M(M-293)	Apr 20, 2026

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: 07 April, 2024

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

DAYVIGO family patents

53. Delstrigo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975	MSD MERCK CO	Non-nucleoside reverse transcriptase inhibitors	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jan 27, 2025
New Chemical Entity Exclusivity(NCE)	Aug 30, 2023
New Indication(I-806)	Sep 19, 2022

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 30 August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: Treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically...

Dosage: TABLET;ORAL

DELSTRIGO family patents

54. Docetaxel patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842770	SHILPA	Non-aqueous taxane pro-emulsion formulations and methods of making and using the same	Aug, 2031 (7 years from now)

Drugs and Companies using DOCETAXEL ingredient

Market Authorisation Date: 22 December, 2015

Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion

Dosage: INJECTABLE;INJECTION

DOCETAXEL family patents

55. Dovato patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234985	VIIV HLTHCARE	Antiviral therapy	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Apr 08, 2022
New Indication(I-839)	Aug 06, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

DOVATO family patents

56. Drospirenone patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11351122	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US11291632	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US9603860	EXELTIS USA INC	Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same	Jun, 2031 (7 years from now)
US10179140	EXELTIS USA INC	Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same	Jun, 2031 (7 years from now)
US11291633	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US11504334	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US11123299	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US10987364	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US11413249	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US11439598	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US10603281	EXELTIS USA INC	Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same	Jun, 2031 (7 years from now)
US10849857	EXELTIS USA INC	Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same	Jun, 2031 (7 years from now)
US11478487	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 29, 2025

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET, CHEWABLE;ORAL

DROSPIRENONE family patents

57. Dsuvia patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945592	VERTICAL PHARMS	Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 02, 2021

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET;SUBLINGUAL

DSUVIA family patents

58. Duobrii patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809307	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)
US11839656	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)
US10478502	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 25, 2022

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

DUOBRII family patents

59. Durysta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8629185	ABBVIE	7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 04, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: NA

Dosage: IMPLANT;OPHTHALMIC

DURYSTA family patents

60. Duzallo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216179	IRONWOOD PHARMS INC	Treatment of gout and hyperuricemia	Aug, 2031 (7 years from now)
US9956205	IRONWOOD PHARMS INC	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof	Dec, 2031 (7 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

DUZALLO family patents

61. Ecoza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071054	RESILIA PHARMS	Econazole composition and methods of treatment therewith	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Oct 24, 2016

Drugs and Companies using ECONAZOLE NITRATE ingredient

Market Authorisation Date: 24 October, 2013

Treatment: NA

Dosage: AEROSOL, FOAM;TOPICAL

ECOZA family patents

62. Edarbyclor patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387249	AZURITY	Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Dec 20, 2014
New Chemical Entity Exclusivity(NCE)	Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

EDARBYCLOR family patents

63. Edluar patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265720	MYLAN SPECIALITY LP	Pharmaceutical formulations useful in the treatment of insomnia	Feb, 2031 (6 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

EDLUAR family patents

64. Eliquis patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17175864A	2020-08-13	STADA Arzneimittel AG	Granted and Under Opposition
EP17175864A	2020-08-12	Intas Pharmaceuticals Ltd.	Granted and Under Opposition
EP17175864A	2020-08-10	Generics (U.K.) Limited	Granted and Under Opposition
EP17175864A	2020-08-07	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP17175864A	2020-08-07	Wittkopp, Alexander	Granted and Under Opposition
EP17175864A	2020-08-06	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP17175864A	2020-08-06	Kutzenberger Wolff & Partner	Granted and Under Opposition
EP17175864A	2020-08-06	von Seebach, Malte	Granted and Under Opposition
EP17175864A	2020-08-04	Zentiva k.s.	Granted and Under Opposition
EP17175864A	2020-08-04	Teva Pharmaceutical Industries LTD.	Granted and Under Opposition
EP17175864A	2020-08-03	SANDOZ AG	Granted and Under Opposition
EP17175864A	2020-08-03	Krka, d.d., Novo mesto	Granted and Under Opposition
EP17178613A	2020-07-16	Generics (U.K.) Limited	Granted and Under Opposition
EP17178613A	2020-07-16	STADA Arzneimittel AG	Granted and Under Opposition
EP17175788A	2020-07-16	Generics (U.K.) Limited	Granted and Under Opposition
EP17175788A	2020-07-16	STADA Arzneimittel AG	Granted and Under Opposition
EP17178613A	2020-07-15	Intas Pharmaceuticals Ltd.	Granted and Under Opposition
EP17178613A	2020-07-15	KRKA, d.d., Novo mesto	Granted and Under Opposition
EP17178613A	2020-07-15	Sandoz AG	Granted and Under Opposition
EP17175788A	2020-07-15	Intas Pharmaceuticals Ltd.	Granted and Under Opposition
EP17175788A	2020-07-15	KRKA, d.d., Novo mesto	Granted and Under Opposition
EP17175788A	2020-07-15	Sandoz AG	Granted and Under Opposition
EP17178613A	2020-07-14	Medichem S.A.	Granted and Under Opposition
EP17178613A	2020-07-14	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP17175788A	2020-07-14	Medichem S.A.	Granted and Under Opposition
EP17175788A	2020-07-14	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP17178613A	2020-07-13	Kutzenberger Wolff & Partner	Granted and Under Opposition
EP17178613A	2020-07-13	Zentiva k.s.	Granted and Under Opposition
EP17175788A	2020-07-13	Kutzenberger Wolff & Partner	Granted and Under Opposition
EP17175788A	2020-07-10	Zentiva k.s.	Granted and Under Opposition
EP17178613A	2020-07-02	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP17175788A	2020-07-02	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP15190823A	2019-09-05	STADA Arzneimittel AG	Granted and Under Opposition
EP15190823A	2019-09-04	Generics (U.K.) Limited	Granted and Under Opposition
EP15190823A	2019-09-04	Zentiva, k.s.	Granted and Under Opposition
EP15190823A	2019-09-04	Intas Pharmaceuticals Ltd.	Granted and Under Opposition
EP15190823A	2019-09-03	KRKA, d.d., Novo mesto	Granted and Under Opposition
EP15190823A	2019-09-03	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP15190823A	2019-08-30	Hamm&Wittkopp Patentanwälte PartmbB	Granted and Under Opposition
EP15190823A	2019-08-29	Sandoz AG	Granted and Under Opposition
EP15190823A	2019-08-27	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP11707284A	2016-09-16	STADA Arzneimittel AG	Revoked
EP11707284A	2016-09-16	KRKA, d.d., Novo mesto	Revoked
EP11707284A	2016-09-16	Galenicum Health S.L.	Revoked
EP11707284A	2016-09-16	Generics (U.K.) Limited	Revoked
EP11707284A	2016-09-16	Hamm&Wittkopp Patentanwälte PartmbB	Revoked
EP11707284A	2016-09-16	Intas Pharmaceuticals Ltd.	Revoked
EP11707284A	2016-09-16	LEK Pharmaceuticals d.d.	Revoked
EP11707284A	2016-09-16	Zentiva k.s.	Revoked
EP11707284A	2016-09-15	Plougmann Vingtoft a/s	Revoked
EP11707284A	2016-09-15	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Revoked
EP11707284A	2016-09-14	Teva Pharmaceutical Industries Ltd	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945	BRISTOL MYERS SQUIBB	Apixaban formulations	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-690)	Aug 21, 2017
New Indication(I-661)	Aug 21, 2017
New Indication(I-691)	Aug 21, 2017
New Indication(I-681)	Mar 03, 2017
New Chemical Entity Exclusivity(NCE)	Dec 28, 2017

Drugs and Companies using APIXABAN ingredient

NCE-1 date: 28 December, 2016

Market Authorisation Date: 28 December, 2012

Treatment: NA

Dosage: TABLET;ORAL

ELIQUIS family patents

65. Enstilar patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10682364	LEO PHARMA AS	Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid	Jun, 2031 (7 years from now)
US10660908	LEO PHARMA AS	Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid	Jun, 2031 (7 years from now)
US10617698	LEO PHARMA AS	Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid	Jun, 2031 (7 years from now)
US10716799	LEO PHARMA AS	Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid	Jun, 2031 (7 years from now)
US9119781	LEO PHARMA AS	Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid	Jun, 2031 (7 years from now)
US10130640	LEO PHARMA AS	Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid	Jun, 2031 (7 years from now)
US9566286	LEO PHARMA AS	Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid	Jun, 2031 (7 years from now)
US10688108	LEO PHARMA AS	Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid	Jun, 2031 (7 years from now)
US10130640 (Pediatric)	LEO PHARMA AS	Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid	Dec, 2031 (7 years from now)
US9119781 (Pediatric)	LEO PHARMA AS	Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Jan 30, 2023
New Patient Population(NPP)	Jul 30, 2022
New Product(NP)	Oct 16, 2018

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Market Authorisation Date: 16 October, 2015

Treatment: Topical treatment of plaque psoriasis in patients 12 years and older

Dosage: AEROSOL, FOAM;TOPICAL

ENSTILAR family patents

66. Epclusa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2031 (6 years from now)
US8618076 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-376)	Jun 10, 2028
M(M-277)	Apr 27, 2025
Pediatric Exclusivity(PED)	Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: NA

Dosage: PELLETS;ORAL; TABLET;ORAL

EPCLUSA family patents

67. Evzio patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9022022	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US9474869	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US10322239	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US8939943	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US10143972	KALEO INC	Ultrafiltration membrane and a preparation method thereof	May, 2031 (7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

EVZIO family patents

68. Evzio (autoinjector) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8939943	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US9474869	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US10322239	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US9022022	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US10143972	KALEO INC	Ultrafiltration membrane and a preparation method thereof	May, 2031 (7 years from now)
US10143792	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	May, 2031 (7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

EVZIO (AUTOINJECTOR) family patents

69. Fanapt patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072742	VANDA PHARMS INC	Method of predicting a predisposition to QT prolongation	Jan, 2031 (6 years from now)
US9074256	VANDA PHARMS INC	Method of predicting a predisposition to QT prolongation	Feb, 2031 (6 years from now)
US9074254	VANDA PHARMS INC	Method of predicting a predisposition to QT prolongation	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-180)	May 26, 2019
New Chemical Entity Exclusivity(NCE)	May 06, 2014

Drugs and Companies using ILOPERIDONE ingredient

NCE-1 date: 06 May, 2013

Market Authorisation Date: 06 May, 2009

Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone

Dosage: TABLET;ORAL

FANAPT family patents

70. Fetzima patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481598	ABBVIE	Stable dosage forms of levomilnacipran	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
NCE(NCE)	Jul 25, 2018
M(M-249)	Oct 07, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Treatment of major depressive disorder (mdd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA family patents

71. Gelnique patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8920392	ABBVIE	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Jan 27, 2012

Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient

Market Authorisation Date: 27 January, 2009

Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin

Dosage: GEL;TRANSDERMAL

GELNIQUE family patents

72. Giapreza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572856	LA JOLLA PHARMA	Method of treating low blood pressure	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 21 December, 2021

Market Authorisation Date: 23 December, 2021

Treatment: Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor

Dosage: SOLUTION;INTRAVENOUS

GIAPREZA family patents

73. Giazo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497256	VALEANT PHARMS INTL	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Feb 03, 2015

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Market Authorisation Date: 03 February, 2012

Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients

Dosage: TABLET;ORAL

GIAZO family patents

74. Gilotrif patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10004743 (Pediatric)	BOEHRINGER INGELHEIM	Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-230)	Jan 12, 2025
M(M-276)	Apr 07, 2025
Pediatric Exclusivity(PED)	Oct 07, 2025
Orphan Drug Exclusivity(ODE)	Apr 15, 2023
New Chemical Entity Exclusivity(NCE)	Jul 12, 2018
New Indication(I-730)	Apr 15, 2019
Orphan Drug Exclusivity(ODE-115)	Apr 15, 2023
New Indication(I-763)	Jan 12, 2021
Orphan Drug Exclusivity(ODE-50)	Jul 12, 2020

Drugs and Companies using AFATINIB DIMALEATE ingredient

NCE-1 date: 07 October, 2024

Market Authorisation Date: 12 July, 2013

Treatment: NA

Dosage: TABLET;ORAL

GILOTRIF family patents

75. Harvoni patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2031 (6 years from now)
US8618076 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-136)	Apr 07, 2024
ODE(ODE)	Apr 07, 2024
Pediatric Exclusivity(PED)	Oct 07, 2024
Orphan Drug Exclusivity(ODE)	Apr 07, 2024
New Chemical Entity Exclusivity(NCE)	Oct 10, 2019
New Dosing Schedule(D-158)	Feb 12, 2019
New Dosing Schedule(D-159)	Feb 12, 2019
New Dosing Schedule(D-160)	Feb 12, 2019
New Patient Population(NPP)	Apr 07, 2020
New Indication(I-718)	Nov 12, 2018
New Dosing Schedule(D-153)	Nov 12, 2018
New Indication(I-719)	Nov 12, 2018
New Indication(I-720)	Nov 12, 2018
New Dosing Schedule(D-177)	Nov 15, 2022

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

NCE-1 date: 08 October, 2023

Market Authorisation Date: 28 August, 2019

Treatment: NA

Dosage: TABLET;ORAL; PELLETS;ORAL

HARVONI family patents

76. Hysingla Er patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8808740	PURDUE PHARMA LP	Encased tamper resistant controlled release dosage forms	Dec, 2031 (7 years from now)
US9572779	PURDUE PHARMA LP	Encased tamper resistant controlled release dosage forms	Dec, 2031 (7 years from now)
US9861584	PURDUE PHARMA LP	Tamper resistant controlled release dosage forms	Dec, 2031 (7 years from now)
US9872837	PURDUE PHARMA LP	Tamper resistant controlled release dosage forms	Dec, 2031 (7 years from now)
US9750703	PURDUE PHARMA LP	Encased tamper resistant controlled release dosage forms	Dec, 2031 (7 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

HYSINGLA ER family patents

77. Imbruvica patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10751342	PHARMACYCLICS LLC	Use of inhibitors of Bruton's tyrosine kinase (Btk)	Jun, 2031 (7 years from now)
US10016435	PHARMACYCLICS LLC	Use of inhibitors of Bruton's tyrosine kinase (Btk)	Jun, 2031 (7 years from now)
US9125889	PHARMACYCLICS LLC	Use of inhibitors of Bruton's tyrosine kinase (Btk)	Jun, 2031 (7 years from now)
US10478439	PHARMACYCLICS LLC	Use of inhibitors of bruton's tyrosine kinase (Btk)	Jun, 2031 (7 years from now)
US8999999	PHARMACYCLICS LLC	Use of inhibitors of Bruton's tyrosine kinase (Btk)	Jun, 2031 (7 years from now)
US9801883	PHARMACYCLICS LLC	Use of inhibitors of bruton's tyrosine kinase (Btk)	Jun, 2031 (7 years from now)
US8754090	PHARMACYCLICS LLC	Use of inhibitors of bruton's tyrosine kinase (Btk)	Jun, 2031 (7 years from now)
US9814721	PHARMACYCLICS LLC	Use of inhibitors of bruton'S tyrosine kinase (BTK)	Jun, 2031 (7 years from now)
US10004746	PHARMACYCLICS LLC	Use of inhibitors of Bruton's tyrosine kinase (Btk)	Jun, 2031 (7 years from now)
US10653696	PHARMACYCLICS LLC	Use of inhibitors of bruton's tyrosine kinase (BTK)	Jun, 2031 (7 years from now)
US9801881	PHARMACYCLICS LLC	Use of inhibitors of bruton's tyrosine kinase (BTK)	Jun, 2031 (7 years from now)
US11672803	PHARMACYCLICS LLC	Use of inhibitors of Brutons tyrosine kinase (Btk)	Jun, 2031 (7 years from now)
US10653696 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of bruton's tyrosine kinase (BTK)	Dec, 2031 (7 years from now)
US8754090 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of bruton's tyrosine kinase (Btk)	Dec, 2031 (7 years from now)
US8999999 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of Bruton's tyrosine kinase (Btk)	Dec, 2031 (7 years from now)
US9801883 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of bruton's tyrosine kinase (Btk)	Dec, 2031 (7 years from now)
US9801881 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of bruton's tyrosine kinase (BTK)	Dec, 2031 (7 years from now)
US9814721 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of bruton'S tyrosine kinase (BTK)	Dec, 2031 (7 years from now)
US10478439 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of bruton's tyrosine kinase (Btk)	Dec, 2031 (7 years from now)
US9125889 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of Bruton's tyrosine kinase (Btk)	Dec, 2031 (7 years from now)
US10751342 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of Bruton's tyrosine kinase (Btk)	Dec, 2031 (7 years from now)
US10004746 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of Bruton's tyrosine kinase (Btk)	Dec, 2031 (7 years from now)
US10016435 (Pediatric)	PHARMACYCLICS LLC	Use of inhibitors of Bruton's tyrosine kinase (Btk)	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-405)	Aug 24, 2029
ODE(ODE)	Aug 02, 2024
New Patient Population(NPP)	Aug 24, 2025
Pediatric Exclusivity(PED)	Feb 24, 2026
M(M-236)	Jan 25, 2022
New Dosing Schedule(D-176)	Aug 24, 2021
New Chemical Entity Exclusivity(NCE)	Nov 13, 2018

Drugs and Companies using IBRUTINIB ingredient

NCE-1 date: 24 February, 2025

Market Authorisation Date: 16 February, 2018

Treatment: Treatment of relapsed or refractory chronic lymphocytic leukemia; Treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia; Treatment of chronic lymphocytic leukemia wit...

Dosage: TABLET;ORAL; SUSPENSION;ORAL; CAPSULE;ORAL

IMBRUVICA family patents

78. Ingrezza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8039627	NEUROCRINE	Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-440)	Aug 18, 2030
New Indication(I-925)	Aug 18, 2026
New Chemical Entity Exclusivity(NCE)	Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: 11 April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: NA

Dosage: CAPSULE;ORAL

INGREZZA family patents

79. Inomax patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8573209	MALLINCKRODT HOSP	Gas delivery device and system	Jan, 2031 (6 years from now)
US8291904	MALLINCKRODT HOSP	Gas delivery device and system	Jan, 2031 (6 years from now)
US8776795	MALLINCKRODT HOSP	Gas delivery device and system	Jan, 2031 (6 years from now)
US9265911	MALLINCKRODT HOSP	Gas delivery device and system	Jan, 2031 (6 years from now)
US9295802	MALLINCKRODT HOSP	Gas delivery device and system	Jan, 2031 (6 years from now)
US8776794	MALLINCKRODT HOSP	Nitric oxide delivery device	Jan, 2031 (6 years from now)
US8573210	MALLINCKRODT HOSP	Nitric oxide delivery device	Jan, 2031 (6 years from now)
US9408993	MALLINCKRODT HOSP	Nitric oxide delivery device	Jan, 2031 (6 years from now)
US8776794 (Pediatric)	MALLINCKRODT HOSP	Nitric oxide delivery device	Jul, 2031 (7 years from now)
US8573209 (Pediatric)	MALLINCKRODT HOSP	Gas delivery device and system	Jul, 2031 (7 years from now)
US8776795 (Pediatric)	MALLINCKRODT HOSP	Gas delivery device and system	Jul, 2031 (7 years from now)
US8573210 (Pediatric)	MALLINCKRODT HOSP	Nitric oxide delivery device	Jul, 2031 (7 years from now)
US8291904 (Pediatric)	MALLINCKRODT HOSP	Gas delivery device and system	Jul, 2031 (7 years from now)
US9265911 (Pediatric)	MALLINCKRODT HOSP	Gas delivery device and system	Jul, 2031 (7 years from now)
US9408993 (Pediatric)	MALLINCKRODT HOSP	Nitric oxide delivery device	Jul, 2031 (7 years from now)
US9295802 (Pediatric)	MALLINCKRODT HOSP	Gas delivery device and system	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-167)	Oct 09, 2018
M(M-132)	Dec 21, 2013
Pediatric Exclusivity(PED)	Jun 21, 2014

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of providing a predetermined concentration of nitric oxide to a patient; A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery...

Dosage: GAS;INHALATION

INOMAX family patents

80. Inrebic patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7528143	IMPACT	Bi-aryl meta-pyrimidine inhibitors of kinases	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-259)	Aug 16, 2026
New Chemical Entity Exclusivity(NCE)	Aug 16, 2024

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

INREBIC family patents

81. Intrarosa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268806	MILLICENT	Pharmaceutical compositions	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 16, 2021

Drugs and Companies using PRASTERONE ingredient

NCE-1 date: 16 November, 2020

Market Authorisation Date: 16 November, 2016

Treatment: NA

Dosage: INSERT;VAGINAL

INTRAROSA family patents

82. Invega Sustenna patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439906	JANSSEN PHARMS	Dosing regimen associated with long acting injectable paliperidone esters	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 19, 2011
New Indication(I-698)	Nov 12, 2017
M(M-215)	Dec 20, 2020
New Dosage Form(NDF)	Jul 31, 2012
Pediatric Exclusivity(PED)	Jan 31, 2013
M(M-119)	Aug 29, 2015

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

NCE-1 date: 01 February, 2012

Market Authorisation Date: 31 July, 2009

Treatment: Dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA SUSTENNA family patents

83. Invokana patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617668	JANSSEN PHARMS	Pharmaceutical formulations	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-809)	Sep 27, 2022
New Indication(I-733)	May 20, 2019
M(M-197)	Feb 01, 2020
New Indication(I-788)	Oct 29, 2021
New Chemical Entity Exclusivity(NCE)	Mar 29, 2018

Drugs and Companies using CANAGLIFLOZIN ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 29 March, 2013

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day

Dosage: TABLET;ORAL

INVOKANA family patents

84. Ionsys patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9364656	THE MEDICINES CO	Method of storing an electrotransport drug delivery device	Sep, 2031 (7 years from now)
US8301238	THE MEDICINES CO	Two-part electrotransport device	Sep, 2031 (7 years from now)
US9731121	THE MEDICINES CO	Switch validation circuit and method	Oct, 2031 (7 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

IONSYS family patents

85. Isentress Hd patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649311 (Pediatric)	MSD SUB MERCK	Solid pharmaceutical compositions containing an integrase inhibitor	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Strength(NS)	May 26, 2020
New Dosing Schedule(D-167)	May 26, 2020
New Patient Population(NPP)	Dec 21, 2014
Pediatric Exclusivity(PED)	May 22, 2021
M(M-114)	Mar 28, 2015
New Chemical Entity Exclusivity(NCE)	Oct 12, 2012

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

NCE-1 date: 22 May, 2020

Market Authorisation Date: 12 October, 2007

Treatment: NA

Dosage: TABLET;ORAL

ISENTRESS HD family patents

86. Isturisa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9434754	RECORDATI RARE	Use of an adrenal hormone-modifying agent	Jan, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862	RECORDATI RARE	Use of an adrenal hormone-modifying agent	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 06, 2025
Orphan Drug Exclusivity(ODE-286)	Mar 06, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 06 March, 2024

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

ISTURISA family patents

87. Jelmyto patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9040074	UROGEN PHARMA	Material and method for treating internal cavities	Jan, 2031 (6 years from now)
US9950069	UROGEN PHARMA	Material and method for treating internal cavities	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-289)	Apr 15, 2027
New Product(NP)	Apr 15, 2023

Drugs and Companies using MITOMYCIN ingredient

Market Authorisation Date: 15 April, 2020

Treatment: NA

Dosage: POWDER;PYELOCALYCEAL

JELMYTO family patents

88. Jevtana Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927592 (Pediatric)	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Apr, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-209)	Sep 14, 2020
M(M-201)	May 17, 2020
M(M-128)	Dec 18, 2023
Pediatric Exclusivity(PED)	Nov 17, 2020
New Chemical Entity Exclusivity(NCE)	Jun 17, 2015

Drugs and Companies using CABAZITAXEL ingredient

NCE-1 date: 18 November, 2019

Market Authorisation Date: 17 June, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

JEVTANA KIT family patents

89. Juluca patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10426780	VIIV HLTHCARE	Antiviral therapy	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 12, 2018
New Combination(NC)	Nov 21, 2020

Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient

NCE-1 date: 12 August, 2017

Market Authorisation Date: 21 November, 2017

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

JULUCA family patents

90. Keppra patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802142	UCB INC	Pharmaceutical compositions comprising levetiracetam and process for their preparation	Jun, 2031 (7 years from now)
US8802142 (Pediatric)	UCB INC	Pharmaceutical compositions comprising levetiracetam and process for their preparation	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Dec 16, 2014
Pediatric Exclusivity(PED)	Jun 16, 2015

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 06 January, 2006

Treatment: NA

Dosage: TABLET;ORAL

KEPPRA family patents

91. Kisqali patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8415355	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Mar, 2031 (6 years from now)
US9193732	NOVARTIS	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868739	NOVARTIS	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Dec 10, 2024
New Chemical Entity Exclusivity(NCE)	Mar 13, 2022
New Indication(I-784)	Jul 18, 2021
New Indication(I-783)	Jul 18, 2021

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negat...

Dosage: TABLET;ORAL

KISQALI family patents

92. Kisqali Femara Co-pack (copackaged) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8415355	NOVARTIS	Pyrrolopyrimidine compounds and their uses	Mar, 2031 (6 years from now)
US9193732	NOVARTIS	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868739	NOVARTIS	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Dec 10, 2024
New Chemical Entity Exclusivity(NCE)	Mar 13, 2022

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: 13 March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cance...

Dosage: TABLET;ORAL

KISQALI FEMARA CO-PACK (COPACKAGED) family patents

93. Kyleena patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10987244	BAYER HLTHCARE	Inserter	Apr, 2031 (6 years from now)
US9668912	BAYER HLTHCARE	Inserter	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 16, 2019

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 16 September, 2016

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

KYLEENA family patents

94. Kynmobi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11419769	SUMITOMO PHARMA AM	Sublingual films	Dec, 2031 (7 years from now)
US8846074	SUMITOMO PHARMA AM	Sublingual films	Dec, 2031 (7 years from now)
US8414922	SUMITOMO PHARMA AM	Sublingual films	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

KYNMOBI family patents

95. Latuda patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9827242	SUNOVION PHARMS INC	Method of treatment for mental disorders	May, 2031 (7 years from now)
US9259423	SUNOVION PHARMS INC	Method of treatment for mental disorders	May, 2031 (7 years from now)
US9259423 (Pediatric)	SUNOVION PHARMS INC	Method of treatment for mental disorders	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-134)	Apr 26, 2015
New Chemical Entity Exclusivity(NCE)	Oct 28, 2015
M(M-195)	Jan 27, 2020
New Patient Population(NPP)	Mar 05, 2021
New Indication(I-674)	Jun 28, 2016
Pediatric Exclusivity(PED)	Jul 27, 2020

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

NCE-1 date: 28 July, 2019

Market Authorisation Date: 07 December, 2011

Treatment: Treatment of bipolar depression with improvement in attention function in bipolar disorder; Treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and...

Dosage: TABLET;ORAL

LATUDA family patents

96. Letairis patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549926	GILEAD	Compositions and methods of treating pulmonary hypertension	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 15, 2012
New Indication(I-716)	Oct 02, 2018
Orphan Drug Exclusivity(ODE)	Jun 15, 2014

Drugs and Companies using AMBRISENTAN ingredient

NCE-1 date: 16 June, 2011

Market Authorisation Date: 15 June, 2007

Treatment: For the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3

Dosage: TABLET;ORAL

LETAIRIS family patents

97. Linzess patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8933030	ABBVIE	Treatments for gastrointestinal disorders	Feb, 2031 (6 years from now)
US10675325	ABBVIE	Stable formulations of linaclotide	Aug, 2031 (7 years from now)
US10702576	ABBVIE	Stable formulations of linaclotide	Aug, 2031 (7 years from now)
US8802628	ABBVIE	Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration	Oct, 2031 (7 years from now)
US8748573	ABBVIE	Formulations comprising linaclotide	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-921)	Jun 12, 2026
New Strength(NS)	Jan 25, 2020
New Chemical Entity Exclusivity(NCE)	Aug 30, 2017

Drugs and Companies using LINACLOTIDE ingredient

NCE-1 date: 30 August, 2016

Market Authorisation Date: 30 August, 2012

Treatment: Treatment of functional constipation in pediatric patients 6 to 17 years of age; Method of treating chronic idiopathic constipation in adult patients.

Dosage: CAPSULE;ORAL

LINZESS family patents

98. Livmarli patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11260053	MIRUM	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 29, 2026
Orphan Drug Exclusivity(ODE-429)	Mar 13, 2030
New Indication(I-938)	Mar 13, 2027
Orphan Drug Exclusivity(ODE-379)	Sep 29, 2028
New Patient Population(NPP)	Mar 13, 2026

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: 29 September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

LIVMARLI family patents

99. Lupron Depot patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921326	ABBVIE ENDOCRINE INC	Sustained-release composition and method for producing the same	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Strength(NS)	Jun 17, 2014
New Dosing Schedule(D-132)	Jun 17, 2014

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 22 December, 1995

Treatment: Palliative treatment of prostate cancer

Dosage: INJECTABLE;INJECTION

LUPRON DEPOT family patents

100. Lupron Depot-ped Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921326	ABBVIE ENDOCRINE INC	Sustained-release composition and method for producing the same	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Strength(NS)	Apr 14, 2026
M(M-107)	Oct 08, 2014
New Product(NP)	Aug 15, 2014

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 16 April, 1993

Treatment: NA

Dosage: POWDER;INTRAMUSCULAR

LUPRON DEPOT-PED KIT family patents

101. Lybalvi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9119848	ALKERMES INC	Morphinan derivatives for the treatment of drug overdose	Aug, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241425	ALKERMES INC	Composition for treating mental illness	Aug, 2031 (7 years from now)
US10300054	ALKERMES INC	Methods for treating antipsychotic-induced weight gain	Aug, 2031 (7 years from now)
US11793805	ALKERMES INC	Methods for treating antipsychotic-induced weight gain	Aug, 2031 (7 years from now)
US9126977	ALKERMES INC	Methods for treating antipsychotic-induced weight gain	Aug, 2031 (7 years from now)
US10716785	ALKERMES INC	Methods for treating antipsychotic-induced weight gain	Aug, 2031 (7 years from now)
US11185541	ALKERMES INC	Methods for treating antipsychotic-induced weight gain	Aug, 2031 (7 years from now)
US11351166	ALKERMES INC	Methods for treating antipsychotic-induced weight gain	Aug, 2031 (7 years from now)
US9517235	ALKERMES INC	Methods for treating antipsychotic-induced weight gain	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating schizophrenia by administ...

Dosage: TABLET;ORAL

LYBALVI family patents

102. Lynparza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859562	ASTRAZENECA	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-180)	Aug 17, 2024
Orphan Drug Exclusivity(ODE-181)	Aug 17, 2024
Orphan Drug Exclusivity(ODE-226)	Dec 19, 2025
Orphan Drug Exclusivity(ODE-283)	Dec 27, 2026
Orphan Drug Exclusivity(ODE-306)	May 08, 2027
New Indication(I-914)	May 31, 2026
New Indication(I-885)	Mar 11, 2025
New Product(NP)	Aug 17, 2020
Orphan Drug Exclusivity(ODE-83)	Dec 19, 2021
New Indication(I-818)	Dec 27, 2022
New Indication(I-762)	Jan 12, 2021
New Indication(I-831)	May 08, 2023
New Indication(I-832)	May 19, 2023
New Indication(I-776)	Dec 19, 2021
Orphan Drug Exclusivity(ODE)	Dec 19, 2021
New Chemical Entity Exclusivity(NCE)	Dec 19, 2019

Drugs and Companies using OLAPARIB ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 17 August, 2017

Treatment: Adjuvant treatment of patients with gbrca-mutated human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy

Dosage: TABLET;ORAL; CAPSULE;ORAL

LYNPARZA family patents

103. Makena (autoinjector) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446440	COVIS	Needle assisted injection device having reduced trigger force	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Feb 03, 2018
Orphan Drug Exclusivity(ODE-7)	Feb 03, 2018

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 14 February, 2018

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

MAKENA (AUTOINJECTOR) family patents

104. Mavyret patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9586978 (Pediatric)	ABBVIE	Anti-viral compounds	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-372)	Jun 10, 2028
Pediatric Exclusivity(PED)	Dec 10, 2028
New Chemical Entity Exclusivity(NCE)	Aug 03, 2022
New Dosing Schedule(D-175)	Sep 26, 2022
M(M-259)	Apr 10, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 10 June, 2021

Treatment: NA

Dosage: PELLETS;ORAL; TABLET;ORAL

MAVYRET family patents

105. Mekinist patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8952018 (Pediatric)	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	Apr, 2031 (6 years from now)
US8703781 (Pediatric)	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-182)	Apr 30, 2025
Orphan Drug Exclusivity(ODE-183)	May 04, 2025
Orphan Drug Exclusivity(ODE-148)	Jun 22, 2024
New Indication(I-908)	Mar 16, 2026
Orphan Drug Exclusivity(ODE-428)	Mar 16, 2030
New Indication(I-895)	Jun 22, 2025
Pediatric Exclusivity(PED)	Dec 22, 2025
New Indication(I-745)	Jun 22, 2020
Orphan Drug Exclusivity(ODE-48)	May 29, 2020
M(M-170)	Nov 20, 2018
Orphan Drug Exclusivity(ODE-57)	Jan 08, 2021
New Indication(I-678)	Jan 08, 2017
M(M-246)	Oct 06, 2022
New Indication(I-778)	Apr 30, 2021
New Indication(I-781)	May 04, 2021
Orphan Drug Exclusivity(ODE)	May 29, 2020
New Chemical Entity Exclusivity(NCE)	May 29, 2018

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: NA

Dosage: TABLET;ORAL

MEKINIST family patents

106. Mektovi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314464	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-194)	Jun 27, 2025
New Indication(I-928)	Oct 11, 2026
New Chemical Entity Exclusivity(NCE)	Jun 27, 2023

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with metastatic non small cell lung cancer with a braf v600e mutation, as detected by an fda-appr...

Dosage: TABLET;ORAL

MEKTOVI family patents

107. Minocin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278105	REMPEX	Tetracycline compositions	May, 2031 (7 years from now)
US9084802	REMPEX	Tetracycline compositions	May, 2031 (7 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Treatment: Method of treating bacterial infections

Dosage: INJECTABLE;INJECTION

MINOCIN family patents

108. Mirena patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10987244	BAYER HLTHCARE	Inserter	Apr, 2031 (6 years from now)
US9668912	BAYER HLTHCARE	Inserter	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-181)	Aug 20, 2023
New Indication(I-610)	Oct 01, 2012

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 06 December, 2000

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

MIRENA family patents

109. Mirvaso patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861631	GALDERMA LABS LP	Methods and compositions for safe and effective treatment of erythema	Mar, 2031 (6 years from now)
US9861632	GALDERMA LABS LP	Methods and compositions for safe and effective treatment of erythema	Mar, 2031 (6 years from now)
US8513247	GALDERMA LABS LP	Methods and compositions for safe and effective treatment of erythema	Mar, 2031 (6 years from now)
US8513249	GALDERMA LABS LP	Methods and compositions for safe and effective treatment of erythema	Mar, 2031 (6 years from now)
US8163725	GALDERMA LABS LP	Gel compositions and methods of use	Jun, 2031 (7 years from now)
US10201517	GALDERMA LABS LP	Brimonidine gel compositions and methods of use	Jun, 2031 (7 years from now)
US8053427	GALDERMA LABS LP	Brimonidine gel composition	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Aug 23, 2016

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

MIRVASO family patents

110. Mounjaro patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Feb, 2031 (6 years from now)
US9402957	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 July, 2023

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

MOUNJARO family patents

111. Mulpleta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427402	VANCOCIN ITALIA	Preparation for improving solubility of poorly soluble drug	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: 31 July, 2022

Market Authorisation Date: 31 July, 2018

Treatment: NA

Dosage: TABLET;ORAL

MULPLETA family patents

112. Multaq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8602215	SANOFI AVENTIS US	Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 01, 2014

Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient

NCE-1 date: 01 July, 2013

Market Authorisation Date: 01 July, 2009

Treatment: Management of risk of dronedarone/beta-blocker interaction in patients in sinus rhythm with a history of paroxysmal or persistent af

Dosage: TABLET;ORAL

MULTAQ family patents

113. Mydcombi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10839960	EYENOVIA	Ophthalmic drug delivery	Jul, 2031 (7 years from now)
US11398306	EYENOVIA	Ophthalmic drug delivery	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 05, 2026

Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE ingredient

Market Authorisation Date: 05 May, 2023

Treatment: Method of administering an effective dose of tropicamide and phenylephrine hydrochloride to an eye

Dosage: SPRAY, METERED;OPHTHALMIC

MYDCOMBI family patents

114. Mytesi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962680	NAPO PHARMS INC	Methods and compositions for treating HIV-associated diarrhea	Oct, 2031 (7 years from now)
US9585868	NAPO PHARMS INC	Methods and compositions for treating HIV-associated diarrhea	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 31, 2017

Drugs and Companies using CROFELEMER ingredient

NCE-1 date: 31 December, 2016

Market Authorisation Date: 31 December, 2012

Treatment: Symptomatic relief of non-infectious diarrhea

Dosage: TABLET, DELAYED RELEASE;ORAL

MYTESI family patents

115. Naloxone Hydrochloride (autoinjector) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9814838	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US9022022	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US10322239	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US8939943	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US9474869	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	Feb, 2031 (6 years from now)
US10143792	KALEO INC	Medicament delivery device for administration of opioid antagonists including formulations for naloxone	May, 2031 (7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents

116. Nerlynx patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8669273	PUMA BIOTECH	Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-182)	Jun 28, 2024
New Chemical Entity Exclusivity(NCE)	Jul 17, 2022
New Indication(I-823)	Feb 25, 2023

Drugs and Companies using NERATINIB MALEATE ingredient

NCE-1 date: 17 July, 2021

Market Authorisation Date: 17 July, 2017

Treatment: Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the me...

Dosage: TABLET;ORAL

NERLYNX family patents

117. Nexiclon Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623409	ATHENA	Clonidine formulation	Sep, 2031 (7 years from now)

Drugs and Companies using CLONIDINE ingredient

Market Authorisation Date: 03 December, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

NEXICLON XR family patents

118. Nithiodote patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8496973	HOPE PHARMS	Sodium thiosulfate-containing pharmaceutical compositions	Mar, 2031 (6 years from now)
US8568793	HOPE PHARMS	Sodium nitrite-containing pharmaceutical compositions	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-5)	Jan 14, 2018
Orphan Drug Exclusivity(ODE)	Jan 14, 2018

Drugs and Companies using SODIUM NITRITE; SODIUM THIOSULFATE ingredient

Market Authorisation Date: 14 January, 2011

Treatment: Treatment of acute cyanide poisoning that is judged to be life threatening

Dosage: SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

NITHIODOTE family patents

119. Noxafil patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358297	MERCK SHARP DOHME	Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin	Jun, 2031 (7 years from now)
US9023790	MERCK SHARP DOHME	Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	May 31, 2024
Orphan Drug Exclusivity(ODE-355)	Jun 17, 2028
New Indication(I-881)	Jun 17, 2024

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 13 March, 2014

Treatment: Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised

Dosage: SOLUTION;INTRAVENOUS

NOXAFIL family patents

120. Nuzyra patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314475	PARATEK PHARMS INC	Oral and injectable formulations of tetracycline compounds	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 02, 2023
Generating Antibiotic Incentives Now(GAIN)	Oct 02, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 03 October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: NA

Dosage: TABLET;ORAL

NUZYRA family patents

121. Ofirmev patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399012	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-196)	Jan 27, 2020
Pediatric Exclusivity(PED)	Jul 27, 2020
New Product(NP)	Nov 02, 2013

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 02 November, 2010

Treatment: Modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics

Dosage: SOLUTION;INTRAVENOUS

OFIRMEV family patents

122. Olumiant patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11806555	ELI LILLY AND CO	Methods for treating hair loss disorders	Nov, 2031 (7 years from now)
US9737469	ELI LILLY AND CO	Methods for treating hair loss disorders	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-890)	Jun 13, 2025
New Indication(I-891)	May 10, 2025
New Chemical Entity Exclusivity(NCE)	May 31, 2023

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: 31 May, 2022

Market Authorisation Date: 08 October, 2019

Treatment: Treatment of adult patients with severe alopecia areata

Dosage: TABLET;ORAL

OLUMIANT family patents

123. Opzelura patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869870	INCYTE CORP	Topical formulation for a JAK inhibitor	May, 2031 (7 years from now)
US11590136	INCYTE CORP	Topical formulation for a JAK inhibitor	May, 2031 (7 years from now)
US11219624	INCYTE CORP	Topical formulation for a JAK inhibitor	May, 2031 (7 years from now)
US11571425	INCYTE CORP	Topical formulation for a JAK inhibitor	May, 2031 (7 years from now)
US10758543	INCYTE CORP	Topical formulation for a JAK inhibitor	May, 2031 (7 years from now)
US10869870 (Pediatric)	INCYTE CORP	Topical formulation for a JAK inhibitor	Nov, 2031 (7 years from now)
US10758543 (Pediatric)	INCYTE CORP	Topical formulation for a JAK inhibitor	Nov, 2031 (7 years from now)
US11219624 (Pediatric)	INCYTE CORP	Topical formulation for a JAK inhibitor	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 21, 2024
New Indication(I-896)	Jul 18, 2025
Pediatric Exclusivity(PED)	Jan 18, 2026

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 21 September, 2021

Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription th...

Dosage: CREAM;TOPICAL

OPZELURA family patents

124. Orenitram patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8349892	UNITED THERAP	Solid formulations of prostacyclin analogs	Jan, 2031 (6 years from now)
US8747897	UNITED THERAP	Osmotic drug delivery system	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-272)	Oct 18, 2026
New Dosage Form(NDF)	Dec 20, 2016
New Indication(I-820)	Oct 18, 2022
New Dosing Schedule(D-156)	Jan 28, 2019
New Dosing Schedule(D-157)	Jan 28, 2019
Orphan Drug Exclusivity(ODE-308)	Dec 20, 2020

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: A method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form

Dosage: TABLET, EXTENDED RELEASE;ORAL

ORENITRAM family patents

125. Otrexup patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8814834	OTTER PHARMS	Injector safety device	May, 2031 (7 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 07 November, 2014

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

OTREXUP family patents

126. Ozempic patents expiration

What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129343	NOVO	Acylated GLP-1 compounds	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-185)	Mar 28, 2025
New Chemical Entity Exclusivity(NCE)	Dec 05, 2022
New Indication(I-822)	Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

OZEMPIC family patents

127. Parsabiv patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8999932	KAI PHARMS INC	Therapeutic agents for reducing parathyroid hormone levels	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 07, 2022

Drugs and Companies using ETELCALCETIDE ingredient

NCE-1 date: 07 February, 2021

Market Authorisation Date: 07 February, 2017

Treatment: A method of treating secondary hyperparathyroidism (shpt)

Dosage: SOLUTION;INTRAVENOUS

PARSABIV family patents

128. Pifeltro patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975	MSD MERCK CO	Non-nucleoside reverse transcriptase inhibitors	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jan 27, 2025
New Indication(I-827)	Sep 19, 2022
New Chemical Entity Exclusivity(NCE)	Aug 30, 2023

Drugs and Companies using DORAVIRINE ingredient

NCE-1 date: 30 August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current a...

Dosage: TABLET;ORAL

PIFELTRO family patents

129. Pliaglis patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10751305	TARO	Solid-forming topical formulations for pain control	Jan, 2031 (6 years from now)
US10603293	TARO	Solid-forming local anesthetic formulations for pain control	Jan, 2031 (6 years from now)
US10350180	TARO	Solid-forming local anesthetic formulations for pain control	Jan, 2031 (6 years from now)

Drugs and Companies using LIDOCAINE; TETRACAINE ingredient

Market Authorisation Date: 29 June, 2006

Treatment: NA

Dosage: CREAM;TOPICAL

PLIAGLIS family patents

130. Pomalyst patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8828427	BRISTOL	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Jun, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828427 (Pediatric)	BRISTOL	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-14)	Nov 20, 2023
Orphan Drug Exclusivity(ODE-297)	May 14, 2027
Orphan Drug Exclusivity(ODE-296)	May 14, 2027
Pediatric Exclusivity(PED)	Nov 14, 2027
New Indication(I-707)	Apr 23, 2018
Orphan Drug Exclusivity(ODE-43)	Feb 08, 2020
Orphan Drug Exclusivity(ODE)	Feb 08, 2020
New Chemical Entity Exclusivity(NCE)	Feb 08, 2018

Drugs and Companies using POMALIDOMIDE ingredient

NCE-1 date: 14 November, 2026

Market Authorisation Date: 08 February, 2013

Treatment: NA

Dosage: CAPSULE;ORAL

POMALYST family patents

131. Pradaxa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034822	BOEHRINGER INGELHEIM	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	Jan, 2031 (6 years from now)
US9034822 (Pediatric)	BOEHRINGER INGELHEIM	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	Jul, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-862)	Jun 21, 2024
Pediatric Exclusivity(PED)	Dec 21, 2024
New Indication(I-683)	Apr 04, 2017
New Indication(I-682)	Apr 04, 2017
New Strength(NS)	Nov 20, 2018
M(M-168)	Nov 20, 2018
New Chemical Entity Exclusivity(NCE)	Oct 19, 2015

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

NCE-1 date: 22 December, 2023

Market Authorisation Date: 19 October, 2010

Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab

Dosage: CAPSULE;ORAL

PRADAXA family patents

132. Proair Digihaler patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731087	TEVA BRANDED PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US10124131	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10022510	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US9216260	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 12, 2018
New Patient Population(NPP)	Apr 28, 2019

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED;INHALATION

PROAIR DIGIHALER family patents

133. Proair Hfa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086156	TEVA BRANDED PHARM	Dose counter for inhaler and method for counting doses	May, 2031 (7 years from now)
US9808587	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US9463289	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US10022510	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US10695512	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US11395889	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10022509	TEVA BRANDED PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Sep 16, 2011

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 29 October, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

PROAIR HFA family patents

134. Proair Respiclick patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10124131	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10022510	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US9731087	TEVA BRANDED PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US9216260	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 12, 2018
New Patient Population(NPP)	Apr 28, 2019

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED;INHALATION

PROAIR RESPICLICK family patents

135. Pyrukynd patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8785450	AGIOS PHARMS INC	Therapeutic compounds and compositions	Feb, 2031 (6 years from now)
USRE49582	AGIOS PHARMS INC	Therapeutic compounds and compositions	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-392)	Feb 17, 2029
New Chemical Entity Exclusivity(NCE)	Feb 17, 2027

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: 17 February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: NA

Dosage: TABLET;ORAL

PYRUKYND family patents

136. Qnasl patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188811	TEVA BRANDED PHARM	Nasal spray device	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Strength(NS)	Dec 17, 2017
New Product(NP)	Mar 23, 2015

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 17 December, 2014

Treatment: NA

Dosage: AEROSOL, METERED;NASAL

QNASL family patents

137. Quillichew Er patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8287903	NEXTWAVE PHARMS	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 04, 2018

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 December, 2015

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

QUILLICHEW ER family patents

138. Quillivant Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778390	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US9040083	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US8956649	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US8287903	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US8563033	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)
US8465765	NEXTWAVE	Orally effective methylphenidate extended release powder and aqueous suspension product	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Sep 27, 2015

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 September, 2012

Treatment: Treatment of a patient by administering the formulation recited in claim 1 or claim 23; Method of treating attention deficit hyperactivity disorder by administering the composition of claim 1; Treatin...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

QUILLIVANT XR family patents

139. Qulipta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9499545	ABBVIE	Piperidinone carboxamide azaindane CGRP receptor antagonists	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-909)	Apr 17, 2026
New Chemical Entity Exclusivity(NCE)	Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: 28 September, 2025

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of migraine in adults

Dosage: TABLET;ORAL

QULIPTA family patents

140. Qvar 40 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9463289	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US10022509	TEVA BRANDED PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US10086156	TEVA BRANDED PHARM	Dose counter for inhaler and method for counting doses	May, 2031 (7 years from now)
US11395889	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10695512	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10022510	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US9808587	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

QVAR 40 family patents

141. Qvar 80 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695512	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10086156	TEVA BRANDED PHARM	Dose counter for inhaler and method for counting doses	May, 2031 (7 years from now)
US10022510	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US9463289	TEVA BRANDED PHARM	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US10022509	TEVA BRANDED PHARM	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US9808587	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US11395889	TEVA BRANDED PHARM	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

QVAR 80 family patents

142. Qvar Redihaler patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10022510	NORTON WATERFORD	Dose counters for inhalers, inhalers and methods of assembly thereof	May, 2031 (7 years from now)
US10086156	NORTON WATERFORD	Dose counter for inhaler and method for counting doses	May, 2031 (7 years from now)
US11395889	NORTON WATERFORD	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10695512	NORTON WATERFORD	Dose counter for inhaler having an anti-reverse rotation actuator	May, 2031 (7 years from now)
US10022509	NORTON WATERFORD	Dose counter for inhaler having a bore and shaft arrangement	May, 2031 (7 years from now)
US8931476	NORTON WATERFORD	Inhaler	Jul, 2031 (7 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

QVAR REDIHALER family patents

143. Relistor patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307417	SALIX	Oral formulations and lipophilic salts of methylnaltrexone	Mar, 2031 (6 years from now)
US8524276	SALIX	Oral formulations and lipophilic salts of methylnaltrexone	Mar, 2031 (6 years from now)
US10376505	SALIX	Oral formulations and lipophilic salts of methylnaltrexone	Mar, 2031 (6 years from now)
US8956651	SALIX	Oral formulations and lipophilic salts of methylnal trexone	Mar, 2031 (6 years from now)
US9314461	SALIX	Oral formulations and lipophilic salts of methylnaltrexone	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jul 19, 2019

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Market Authorisation Date: 19 July, 2016

Treatment: NA

Dosage: TABLET;ORAL

RELISTOR family patents

144. Restasis Multidose patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8292129	ABBVIE	Dispensing device	Feb, 2031 (6 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

RESTASIS MULTIDOSE family patents

145. Rhofade patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883838	MAYNE PHARMA	Pharmaceutical cream compositions and methods of use	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jan 18, 2020

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 January, 2017

Treatment: NA

Dosage: CREAM;TOPICAL

RHOFADE family patents

146. Rinvoq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8962629	ABBVIE	Tricyclic compounds	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 16, 2024
New Indication(I-919)	May 18, 2026
New Indication(I-886)	Mar 16, 2025
New Indication(I-888)	Apr 29, 2025
New Indication(I-880)	Dec 14, 2024
New Indication(I-883)	Jan 14, 2025

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tnf blockers

Dosage: TABLET, EXTENDED RELEASE;ORAL

RINVOQ family patents

147. Rubraca patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8754072	ZR PHARMA	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one	Feb, 2031 (6 years from now)
US9045487	ZR PHARMA	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one	Feb, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10278974	ZR PHARMA	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one	Feb, 2031 (6 years from now)
US9861638	ZR PHARMA	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one	Feb, 2031 (6 years from now)
US8859562	ZR PHARMA	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-168)	Apr 06, 2025
Orphan Drug Exclusivity(ODE-126)	Dec 19, 2023
New Chemical Entity Exclusivity(NCE)	Dec 19, 2021
New Indication(I-830)	May 15, 2023
Orphan Drug Exclusivity(ODE)	Dec 19, 2023
New Indication(I-772)	Apr 06, 2021

Drugs and Companies using RUCAPARIB CAMSYLATE ingredient

NCE-1 date: 19 December, 2020

Market Authorisation Date: 19 December, 2016

Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; A method for treating metastatic castration-r...

Dosage: TABLET;ORAL

RUBRACA family patents

148. Rybelsus patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129343	NOVO	Acylated GLP-1 compounds	Dec, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11382957	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid	Dec, 2031 (7 years from now)
US10086047	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid	Dec, 2031 (7 years from now)
US10960052	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid	Dec, 2031 (7 years from now)
US9278123	NOVO	Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 20, 2022
New Chemical Entity Exclusivity(NCE)	Dec 05, 2022
M(M-252)	Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 20 September, 2019

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

RYBELSUS family patents

149. Seglentis patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846744	KOWA PHARMS	Pharmaceutical compositions of co-crystals of tramadol and coxibs	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 15, 2024

Drugs and Companies using CELECOXIB; TRAMADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: NA

Dosage: TABLET;ORAL

SEGLENTIS family patents

150. Seysara patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8318706	ALMIRALL	Substituted tetracycline compounds	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 01, 2023

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

NCE-1 date: 01 October, 2022

Market Authorisation Date: 01 October, 2018

Treatment: A method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sa...

Dosage: TABLET;ORAL

SEYSARA family patents

151. Sinuva patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357640	INTERSECT ENT INC	Expandable devices and methods for treating a nasal or sinus condition	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 08, 2020

Drugs and Companies using MOMETASONE FUROATE ingredient

Market Authorisation Date: 08 December, 2017

Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant

Dosage: IMPLANT;IMPLANTATION

SINUVA family patents

152. Skyla patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10987244	BAYER HLTHCARE	Inserter	Apr, 2031 (6 years from now)
US9668912	BAYER HLTHCARE	Inserter	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jan 09, 2016

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 09 January, 2013

Treatment: NA

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

SKYLA family patents

153. Slynd patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11123299	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US11439598	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US10179140	EXELTIS USA INC	Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same	Jun, 2031 (7 years from now)
US10987364	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US11504334	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US9603860	EXELTIS USA INC	Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same	Jun, 2031 (7 years from now)
US11291632	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US11413249	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US11478487	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US10603281	EXELTIS USA INC	Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same	Jun, 2031 (7 years from now)
US10849857	EXELTIS USA INC	Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same	Jun, 2031 (7 years from now)
US11291633	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)
US11351122	EXELTIS USA INC	Synthetic progestogens and pharmaceutical compositions comprising the same	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 23, 2022

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 23 May, 2019

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET;ORAL

SLYND family patents

154. Sodium Nitrite patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8568793	HOPE PHARMS	Sodium nitrite-containing pharmaceutical compositions	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-5)	Jan 14, 2018
Orphan Drug Exclusivity(ODE)	Jan 14, 2018

Drugs and Companies using SODIUM NITRITE ingredient

Market Authorisation Date: 14 February, 2012

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

SODIUM NITRITE family patents

155. Sodium Thiosulfate patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8496973	HOPE PHARMS	Sodium thiosulfate-containing pharmaceutical compositions	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-5)	Jan 14, 2018
Orphan Drug Exclusivity(ODE)	Jan 14, 2018

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 14 February, 2012

Treatment: Treatment of acute cyanide poisoning that is judged to be life threatening

Dosage: SOLUTION;INTRAVENOUS

SODIUM THIOSULFATE family patents

156. Sohonos patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314439	IPSEN INC	Composition and method for muscle repair and regeneration	Aug, 2031 (7 years from now)
US9789074	IPSEN INC	Composition and method for muscle repair and regeneration	Aug, 2031 (7 years from now)
US10292954	IPSEN INC	Composition and method for muscle repair and regeneration	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-439)	Aug 16, 2030
New Chemical Entity Exclusivity(NCE)	Aug 16, 2028

Drugs and Companies using PALOVAROTENE ingredient

NCE-1 date: 17 August, 2027

Market Authorisation Date: 16 August, 2023

Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva

Dosage: CAPSULE;ORAL

SOHONOS family patents

157. Solodyn patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192615	BAUSCH	Method for the treatment of acne and certain dosage forms thereof	Nov, 2031 (7 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 May, 2006

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

SOLODYN family patents

158. Sovaldi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2031 (6 years from now)
US8618076 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-258)	Aug 28, 2026
ODE(ODE)	Apr 07, 2024
Pediatric Exclusivity(PED)	Oct 07, 2024

Drugs and Companies using SOFOSBUVIR ingredient

Market Authorisation Date: 28 August, 2019

Treatment: NA

Dosage: PELLETS;ORAL; TABLET;ORAL

SOVALDI family patents

159. Spiriva Respimat patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8733341 (Pediatric)	BOEHRINGER INGELHEIM	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 24, 2017
New Patient Population(NPP)	Feb 15, 2020
Pediatric Exclusivity(PED)	Aug 15, 2020

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 15 September, 2015

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

SPIRIVA RESPIMAT family patents

160. Stivarga patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8637553	BAYER HLTHCARE	Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions	Feb, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9458107	BAYER HLTHCARE	Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-139)	Apr 27, 2024
New Indication(I-744)	Apr 27, 2020
Orphan Drug Exclusivity(ODE-44)	Feb 25, 2020
Orphan Drug Exclusivity(ODE)	Feb 25, 2020
New Chemical Entity Exclusivity(NCE)	Sep 27, 2017
New Indication(I-667)	Feb 25, 2016

Drugs and Companies using REGORAFENIB ingredient

NCE-1 date: 27 September, 2016

Market Authorisation Date: 27 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

STIVARGA family patents

161. Sublocade patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9272044	INDIVIOR	Injectable flowable composition buprenorphine	Jun, 2031 (7 years from now)
US9827241	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US9782402	INDIVIOR	Injectable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US10592168	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US9498432	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US10198218	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US10558394	INDIVIOR	Injectable flowable composition comprising buprenorphine	Jun, 2031 (7 years from now)
US8975270	INDIVIOR	Injectable flowable composition comprising buprenorphine	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 30, 2020

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 30 November, 2017

Treatment: Treating opioid addiction by subcutaneous injection of buprenorphine; Treating opioid dependency by administering buprenorphine once per month; Treating addiction by subcutaneous injection of buprenor...

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

SUBLOCADE family patents

162. Sunosi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440715	AXSOME MALTA	Treatment of sleep-wake disorders	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 17, 2024
Orphan Drug Exclusivity(ODE-254)	Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)

Dosage: TABLET;ORAL

SUNOSI family patents

163. Symdeko (copackaged) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11578062	VERTEX PHARMS INC	Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide	Mar, 2031 (6 years from now)
US10081621	VERTEX PHARMS INC	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-173)	Feb 12, 2025
Orphan Drug Exclusivity(ODE-247)	Jun 21, 2026
Orphan Drug Exclusivity(ODE-335)	Dec 21, 2027
New Chemical Entity Exclusivity(NCE)	Feb 12, 2023
New Patient Population(NPP)	Jun 21, 2022

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

NCE-1 date: 12 February, 2022

Market Authorisation Date: 21 June, 2019

Treatment: Treatment of cf in a patient age 6 years and older who is homozygous for f508del or has at least one cftr gene mutation responsive to tez/iva based on in vitro data and/or clinical evidence using the ...

Dosage: TABLET;ORAL

SYMDEKO (COPACKAGED) family patents

164. Symproic patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9108975	BDSI	Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 23, 2022

Drugs and Companies using NALDEMEDINE TOSYLATE ingredient

NCE-1 date: 23 March, 2021

Market Authorisation Date: 23 March, 2017

Treatment: NA

Dosage: TABLET;ORAL

SYMPROIC family patents

165. Synjardy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610489 (Pediatric)	BOEHRINGER INGELHEIM	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jun 20, 2026
Pediatric Exclusivity(PED)	Dec 20, 2026
New Indication(I-739)	Dec 02, 2019
New Product(NP)	Aug 26, 2018
New Chemical Entity Exclusivity(NCE)	Aug 01, 2019
M(M-174)	Mar 18, 2019

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 26 August, 2015

Treatment: NA

Dosage: TABLET;ORAL

SYNJARDY family patents

166. Tabrecta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420645	NOVARTIS PHARM	Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 06, 2025
Orphan Drug Exclusivity(ODE-291)	May 06, 2027

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

NCE-1 date: 06 May, 2024

Market Authorisation Date: 06 May, 2020

Treatment: NA

Dosage: TABLET;ORAL

TABRECTA family patents

167. Tafinlar patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8952018 (Pediatric)	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	Apr, 2031 (6 years from now)
US8703781 (Pediatric)	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-182)	Apr 30, 2025
Orphan Drug Exclusivity(ODE-183)	May 04, 2025
Orphan Drug Exclusivity(ODE-147)	Jun 22, 2024
Orphan Drug Exclusivity(ODE-428)	Mar 16, 2030
New Indication(I-908)	Mar 16, 2026
New Indication(I-894)	Jun 22, 2025
Pediatric Exclusivity(PED)	Dec 22, 2025
New Indication(I-745)	Jun 22, 2020
New Indication(I-678)	Jan 08, 2017
M(M-170)	Nov 20, 2018
M(M-246)	Oct 06, 2022
Orphan Drug Exclusivity(ODE-47)	May 29, 2020
Orphan Drug Exclusivity(ODE-58)	Jan 09, 2021
New Indication(I-778)	Apr 30, 2021
New Indication(I-781)	May 04, 2021
Orphan Drug Exclusivity(ODE)	May 29, 2020
New Chemical Entity Exclusivity(NCE)	May 29, 2018

Drugs and Companies using DABRAFENIB MESYLATE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: NA

Dosage: CAPSULE;ORAL

TAFINLAR family patents

168. Talzenna patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8735392	PFIZER	Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt	Oct, 2031 (7 years from now)
US10189837	PFIZER	Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-920)	Jun 20, 2026
New Chemical Entity Exclusivity(NCE)	Oct 16, 2023

Drugs and Companies using TALAZOPARIB TOSYLATE ingredient

NCE-1 date: 16 October, 2022

Market Authorisation Date: 20 June, 2023

Treatment: NA

Dosage: CAPSULE;ORAL

TALZENNA family patents

169. Tavalisse patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7449458	RIGEL PHARMS INC	Prodrugs of 2,4-pyrimidinediamine compounds and their uses	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-174)	Apr 17, 2025
New Chemical Entity Exclusivity(NCE)	Apr 17, 2023

Drugs and Companies using FOSTAMATINIB DISODIUM ingredient

NCE-1 date: 17 April, 2022

Market Authorisation Date: 17 April, 2018

Treatment: NA

Dosage: TABLET;ORAL

TAVALISSE family patents

170. Tavneos patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8445515	CHEMOCENTRYX	C5aR antagonists	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-377)	Oct 07, 2028
New Chemical Entity Exclusivity(NCE)	Oct 07, 2026

Drugs and Companies using AVACOPAN ingredient

NCE-1 date: 07 October, 2025

Market Authorisation Date: 07 October, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

TAVNEOS family patents

171. Tazverik patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9334527	EPIZYME INC	Inhibitors of human EZH2, and methods of use thereof	Sep, 2031 (7 years from now)
US8691507	EPIZYME INC	Inhibitors of human EZH2 and methods of use thereof	Sep, 2031 (7 years from now)
US9333217	EPIZYME INC	Inhibitors of human EZH2, and methods of use thereof	Sep, 2031 (7 years from now)
US9949999	EPIZYME INC	Inhibitors of human EZH2, and methods of use thereof	Sep, 2031 (7 years from now)
US9175331	EPIZYME INC	Inhibitors of human EZH2, and methods of use thereof	Sep, 2031 (7 years from now)
US8895245	EPIZYME INC	Inhibitors of human EZH2 and methods of use thereof	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 23, 2025
Orphan Drug Exclusivity(ODE-314)	Jun 18, 2027
Orphan Drug Exclusivity(ODE-299)	Jan 23, 2027
New Indication(I-835)	Jun 18, 2023
New Indication(I-836)	Jun 18, 2023

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

NCE-1 date: 24 January, 2024

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma positive for an...

Dosage: TABLET;ORAL

TAZVERIK family patents

172. Technivie patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420596	ABBVIE	Macrocyclic hepatitis C serine protease inhibitors	Apr, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9044480	ABBVIE	Compositions and methods for treating HCV	Apr, 2031 (6 years from now)
US8686026	ABBVIE	Solid compositions	Jun, 2031 (7 years from now)
US8420596 (Pediatric)	ABBVIE	Macrocyclic hepatitis C serine protease inhibitors	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jul 24, 2018
New Indication(I-743)	Jul 24, 2018
New Chemical Entity Exclusivity(NCE)	Dec 19, 2019

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of hcv infection using paritaprevir

Dosage: TABLET;ORAL

TECHNIVIE family patents

173. Teflaro patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8247400	ABBVIE	Cephem compounds useful for the treatment of bacterial infections	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Sep 13, 2022
New Chemical Entity Exclusivity(NCE)	Oct 29, 2015

Drugs and Companies using CEFTAROLINE FOSAMIL ingredient

NCE-1 date: 29 October, 2014

Market Authorisation Date: 29 October, 2010

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

TEFLARO family patents

174. Tegsedi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9061044	AKCEA THERAPS	Modulation of transthyretin expression	Apr, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8697860	AKCEA THERAPS	Diagnosis and treatment of disease	Apr, 2031 (7 years from now)
US9399774	AKCEA THERAPS	Modulation of transthyretin expression	Apr, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-212)	Oct 05, 2025
New Chemical Entity Exclusivity(NCE)	Oct 05, 2023

Drugs and Companies using INOTERSEN SODIUM ingredient

NCE-1 date: 05 October, 2022

Market Authorisation Date: 05 October, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis

Dosage: SOLUTION;SUBCUTANEOUS

TEGSEDI family patents

175. Tembexa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9303051	EMERGENT BIODEFENSE	Phosphonate ester derivatives and methods of synthesis thereof	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 04, 2024
Orphan Drug Exclusivity(ODE-354)	Jun 04, 2028

Drugs and Companies using BRINCIDOFOVIR ingredient

Market Authorisation Date: 04 June, 2021

Treatment: Method of treating human smallpox disease

Dosage: TABLET;ORAL; SUSPENSION;ORAL

TEMBEXA family patents

176. Thyquidity patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050307	AZURITY	Method for the preparation of a levothyroxine solution	Aug, 2031 (7 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 30 November, 2020

Treatment: NA

Dosage: SOLUTION;ORAL

THYQUIDITY family patents

177. Tosymra patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211282	TONIX MEDS	Formulations comprising triptan compounds	Jul, 2031 (7 years from now)

Drugs and Companies using SUMATRIPTAN ingredient

Market Authorisation Date: 25 January, 2019

Treatment: Acute treatment of migraine

Dosage: SPRAY;NASAL

TOSYMRA family patents

178. Toujeo Max Solostar patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9345750	SANOFI US SERVICES	Long-acting formulations of insulin	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Feb 25, 2018
New Patient Population(NPP)	Nov 26, 2022

Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 25 February, 2015

Treatment: Improvement in glycemic control in diabetes mellitus patients

Dosage: SOLUTION;SUBCUTANEOUS

TOUJEO MAX SOLOSTAR family patents

179. Toujeo Solostar patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9345750	SANOFI US SERVICES	Long-acting formulations of insulin	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Feb 25, 2018
New Patient Population(NPP)	Nov 26, 2022

Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 25 February, 2015

Treatment: Improvement in glycemic control in diabetes mellitus patients

Dosage: SOLUTION;SUBCUTANEOUS

TOUJEO SOLOSTAR family patents

180. Tpoxx patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9339466	SIGA TECHNOLOGIES	Polymorphic forms of ST-246 and methods of preparation	Mar, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233097	SIGA TECHNOLOGIES	ST-246 liquid formulations	Aug, 2031 (7 years from now)
US9907859	SIGA TECHNOLOGIES	ST-246 liquid formulations and methods	Aug, 2031 (7 years from now)
US10576165	SIGA TECHNOLOGIES	ST-246 liquid formulations and methods	Aug, 2031 (7 years from now)
US7737168	SIGA TECHNOLOGIES	Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-200)	Jul 13, 2025
New Chemical Entity Exclusivity(NCE)	Jul 13, 2023

Drugs and Companies using TECOVIRIMAT ingredient

NCE-1 date: 13 July, 2022

Market Authorisation Date: 13 July, 2018

Treatment: Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg; Treatment of human smallpox disease caused by variola virus in adults and pediat...

Dosage: CAPSULE;ORAL; SOLUTION;INTRAVENOUS

TPOXX family patents

181. Tradjenta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8853156	BOEHRINGER INGELHEIM	Treatment for diabetes in patients inappropriate for metformin therapy	Mar, 2031 (6 years from now)
US8853156 (Pediatric)	BOEHRINGER INGELHEIM	Treatment for diabetes in patients inappropriate for metformin therapy	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-295)	Jun 20, 2026
Pediatric Exclusivity(PED)	Dec 20, 2026
M(M-252)	Mar 30, 2023
M(M-258)	Jul 03, 2022
M(M-121)	Aug 13, 2015
New Chemical Entity Exclusivity(NCE)	May 02, 2016
M(M-118)	Aug 13, 2015

Drugs and Companies using LINAGLIPTIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 02 May, 2011

Treatment: Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin

Dosage: TABLET;ORAL

TRADJENTA family patents

182. Treanda patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8436190 (Pediatric)	CEPHALON	Bendamustine pharmaceutical compositions	Apr, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-580)	Oct 31, 2011
Orphan Drug Exclusivity(ODE)	Mar 20, 2015
Pediatric Exclusivity(PED)	Sep 20, 2013
ODE(ODE)	Dec 07, 2022
New Chemical Entity Exclusivity(NCE)	Mar 20, 2013

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

NCE-1 date: 02 May, 2015

Market Authorisation Date: 01 May, 2009

Treatment: NA

Dosage: POWDER;IV (INFUSION)

TREANDA family patents

183. Trelegy Ellipta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8746242 (Pediatric)	GLAXOSMITHKLINE	Medicament dispenser	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 18, 2018
New Indication(I-775)	Apr 24, 2021
New Indication(I-843)	Sep 09, 2023
New Strength(NS)	Sep 09, 2023

Drugs and Companies using FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 September, 2017

Treatment: NA

Dosage: POWDER;INHALATION

TRELEGY ELLIPTA family patents

184. Trikafta (copackaged) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10081621	VERTEX PHARMS INC	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide	Mar, 2031 (6 years from now)
US11578062	VERTEX PHARMS INC	Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-433)	Apr 26, 2030
New Chemical Entity Exclusivity(NCE)	Oct 21, 2024
New Product(NP)	Apr 26, 2026

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

NCE-1 date: 22 October, 2023

Market Authorisation Date: 26 April, 2023

Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with a ...

Dosage: GRANULES;ORAL; TABLET;ORAL

TRIKAFTA (COPACKAGED) family patents

185. Trintellix patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8722684	TAKEDA PHARMS USA	1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment	Jun, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722684 (Pediatric)	TAKEDA PHARMS USA	1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-187)	Jan 22, 2024
M(M-232)	Aug 23, 2026
Pediatric Exclusivity(PED)	Feb 23, 2027
New Chemical Entity Exclusivity(NCE)	Sep 30, 2018
M(M-227)	May 02, 2021
M(M-234)	Oct 19, 2021
M(M-267)	Nov 13, 2023

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

NCE-1 date: 23 February, 2026

Market Authorisation Date: 30 September, 2013

Treatment: NA

Dosage: TABLET;ORAL

TRINTELLIX family patents

186. Trulance patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919024	SALIX	Formulations of guanylate cyclase C agonists and methods of use	Sep, 2031 (7 years from now)
US9925231	SALIX	Formulations of guanylate cyclase C agonists and methods of use	Sep, 2031 (7 years from now)
US9610321	SALIX	Formulations of guanylate cyclase C agonists and methods of use	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 19, 2022
New Indication(I-764)	Jan 24, 2021

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: 19 January, 2021

Market Authorisation Date: 19 January, 2017

Treatment: Chronic idiopathic constipation; Irritable bowel syndrome with constipation

Dosage: TABLET;ORAL

TRULANCE family patents

187. Tukysa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8648087	SEAGEN	N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-309)	Apr 17, 2027
New Chemical Entity Exclusivity(NCE)	Apr 17, 2025
New Indication(I-906)	Jan 19, 2026
Orphan Drug Exclusivity(ODE-422)	Jan 19, 2030

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: NA

Dosage: TABLET;ORAL

TUKYSA family patents

188. Tymlos patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE49444	RADIUS	Method of treating osteoporosis comprising administration of PTHrP analog	Apr, 2031 (7 years from now)
US7803770	RADIUS	Method of treating osteoporosis comprising administration of PTHrP analog	Apr, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-270)	Sep 20, 2024
New Indication(I-907)	Dec 19, 2025
New Chemical Entity Exclusivity(NCE)	Apr 28, 2022

Drugs and Companies using ABALOPARATIDE ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment to increase bone density in men with osteoporosis at high risk for fracture; Method of treating postmenopausal women with osteoporosis at high risk for fracture.

Dosage: SOLUTION;SUBCUTANEOUS

TYMLOS family patents

189. Ubrelvy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9499545	ABBVIE	Piperidinone carboxamide azaindane CGRP receptor antagonists	Nov, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833448	ABBVIE	Piperidinone carboxamide azaindane CGRP receptor antagonists	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: 24 December, 2023

Market Authorisation Date: 23 December, 2019

Treatment: Acute treatment of migraine with or without aura in adults

Dosage: TABLET;ORAL

UBRELVY family patents

190. Uceris patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895064	SALIX	Controlled release and taste masking oral pharmaceutical composition	Sep, 2031 (7 years from now)
US9192581	SALIX	Controlled release and taste masking oral pharmaceutical composition	Sep, 2031 (7 years from now)
US9132093	SALIX	Controlled release and taste making oral pharmaceutical composition	Sep, 2031 (7 years from now)
US10307375	SALIX	Controlled release and taste masking oral pharmaceutical composition	Sep, 2031 (7 years from now)
US10660858	SALIX	Controlled release and taste masking oral pharmaceutical composition	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Jan 14, 2016

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 14 January, 2013

Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis

Dosage: TABLET, EXTENDED RELEASE;ORAL

UCERIS family patents

191. Uloric patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107912	TAKEDA PHARMS USA	Methods for concomitant treatment of theophylline and febuxostat	Sep, 2031 (7 years from now)
US8372872	TAKEDA PHARMS USA	Methods for concomitant treatment of theophylline and febuxostat	Sep, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-205)	Aug 15, 2020
New Chemical Entity Exclusivity(NCE)	Feb 13, 2014

Drugs and Companies using FEBUXOSTAT ingredient

NCE-1 date: 13 February, 2013

Market Authorisation Date: 13 February, 2009

Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline

Dosage: TABLET;ORAL

ULORIC family patents

192. Upneeq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357714	RVL PHARMS	Compositions and methods for non-surgical treatment of ptosis	Aug, 2031 (7 years from now)
US10912765	RVL PHARMS	Compositions and methods for non-surgical treatment of ptosis	Aug, 2031 (7 years from now)
US9867808	RVL PHARMS	Compositions and methods for non-surgical treatment of Ptosis	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jul 08, 2023

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 July, 2020

Treatment: Method of treating blepharoptosis

Dosage: SOLUTION/DROPS;OPHTHALMIC

UPNEEQ family patents

193. Vabomere patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8680136	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561675	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (7 years from now)
US9694025	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (7 years from now)
US11007206	REMPEX	Cyclic boronic acid ester derivatives and therapeutic uses thereof	Aug, 2031 (7 years from now)
US10183034	REMPEX	Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives	Aug, 2031 (7 years from now)
US10172874	REMPEX	Pharmaceutical compositions comprising cyclic boronic acid ester derivatives	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 29, 2022
Generating Antibiotic Incentives Now(GAIN)	Aug 29, 2027

Drugs and Companies using MEROPENEM; VABORBACTAM ingredient

NCE-1 date: 29 August, 2026

Market Authorisation Date: 29 August, 2017

Treatment: Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae sp...

Dosage: POWDER;INTRAVENOUS

VABOMERE family patents

194. Vanflyta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357690	DAIICHI SANKYO INC	Methods of treatment using combination therapy	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-437)	Jul 20, 2030
New Chemical Entity Exclusivity(NCE)	Jul 20, 2028

Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient

NCE-1 date: 21 July, 2027

Market Authorisation Date: 20 July, 2023

Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...

Dosage: TABLET;ORAL

VANFLYTA family patents

195. Veklury patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10065958	GILEAD SCIENCES INC	Methods and compounds for treating Paramyxoviridae virus infections	Sep, 2031 (7 years from now)
US11492353	GILEAD SCIENCES INC	Methods and compounds for treating Paramyxoviridae virus infections	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 22, 2025
New Patient Population(NPP)	Apr 25, 2025
New Dosing Schedule(D-183)	Jan 21, 2025
M(M-301)	Jul 13, 2026
Pediatric Exclusivity(PED)	Jan 13, 2027

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 13 January, 2026

Market Authorisation Date: 22 October, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS; POWDER;INTRAVENOUS

VEKLURY family patents

196. Venclexta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546399	ABBVIE	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases	Jun, 2031 (7 years from now)
US10730873	ABBVIE	Salts and crystalline forms of an apoptosis-inducing agent	Nov, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-185)	Jun 08, 2025
Orphan Drug Exclusivity(ODE-211)	Nov 21, 2025
Orphan Drug Exclusivity(ODE-239)	May 15, 2026
New Chemical Entity Exclusivity(NCE)	Apr 11, 2021
Orphan Drug Exclusivity(ODE)	Apr 11, 2023
New Indication(I-789)	Nov 21, 2021
New Indication(I-795)	May 15, 2022
M(M-265)	Oct 16, 2023
Orphan Drug Exclusivity(ODE-114)	Apr 11, 2023
M(M-228)	Jun 08, 2021
New Indication(I-782)	Jun 08, 2021

Drugs and Companies using VENETOCLAX ingredient

NCE-1 date: 11 April, 2020

Market Authorisation Date: 11 April, 2016

Treatment: NA

Dosage: TABLET;ORAL

VENCLEXTA family patents

197. Veozah patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8871761	ASTELLAS	NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	May 12, 2028

Drugs and Companies using FEZOLINETANT ingredient

NCE-1 date: 13 May, 2027

Market Authorisation Date: 12 May, 2023

Treatment: NA

Dosage: TABLET;ORAL

VEOZAH family patents

198. Verquvo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420656	MERCK SHARP DOHME	Substituted 5-fluoro-1H-pyrazolopyridines and their use	May, 2031 (7 years from now)
US10736896	MERCK SHARP DOHME	Substituted 5-fluoro-1H-pyrazolopyridines and their use	May, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439642	MERCK SHARP DOHME	Substituted 5-fluoro-1H-pyrazolopyridines and their use	May, 2031 (7 years from now)
US8921377	MERCK SHARP DOHME	Substituted 5-fluoro-1H-pyrazolopyridines and their use	May, 2031 (7 years from now)
US9993476	MERCK SHARP DOHME	Substituted 5-flouro-1H-pyrazolopyridines and their use	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 19, 2026

Drugs and Companies using VERICIGUAT ingredient

NCE-1 date: 19 January, 2025

Market Authorisation Date: 19 January, 2021

Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...

Dosage: TABLET;ORAL

VERQUVO family patents

199. Vesicare Ls patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9918970	ASTELLAS	Pharmaceutical composition comprising solifenacin	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Nov 26, 2023
New Product(NP)	May 26, 2023
W(W)	Nov 26, 2023

Drugs and Companies using SOLIFENACIN SUCCINATE ingredient

Market Authorisation Date: 26 May, 2020

Treatment: NA

Dosage: SUSPENSION;ORAL

VESICARE LS family patents

200. Viekira Pak (copackaged) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420596	ABBVIE	Macrocyclic hepatitis C serine protease inhibitors	Apr, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9044480	ABBVIE	Compositions and methods for treating HCV	Apr, 2031 (6 years from now)
US8686026	ABBVIE	Solid compositions	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 19, 2019
New Dosing Schedule(D-163)	Apr 22, 2019

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hcv infection using paritaprevir

Dosage: TABLET;ORAL

VIEKIRA PAK (COPACKAGED) family patents

201. Viekira Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420596	ABBVIE	Macrocyclic hepatitis C serine protease inhibitors	Apr, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9044480	ABBVIE	Compositions and methods for treating HCV	Apr, 2031 (6 years from now)
US8686026	ABBVIE	Solid compositions	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 19, 2019

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 22 July, 2016

Treatment: Treatment of hcv infection using paritaprevir

Dosage: TABLET, EXTENDED RELEASE;ORAL

VIEKIRA XR family patents

202. Viltepso patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10870676	NIPPON SHINYAKU	Antisense nucleic acids	Aug, 2031 (7 years from now)
US9079934	NIPPON SHINYAKU	Antisense nucleic acids	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 12, 2025
Orphan Drug Exclusivity(ODE-280)	Aug 12, 2027

Drugs and Companies using VILTOLARSEN ingredient

NCE-1 date: 12 August, 2024

Market Authorisation Date: 12 August, 2020

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

VILTEPSO family patents

203. Vimovo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9220698	HORIZON	Method for delivering a pharmaceutical composition to patient in need thereof	Mar, 2031 (6 years from now)
US8945621	HORIZON	Method for treating a patient at risk for developing an NSAID-associated ulcer	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jul 06, 2020
New Combination(NC)	Apr 30, 2013

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient

Market Authorisation Date: 30 April, 2010

Treatment: Risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment; Risk-reduction of nsaid-associated gastric ulcers in patients also taking low dose aspirin

Dosage: TABLET, DELAYED RELEASE;ORAL

VIMOVO family patents

204. Vivjoa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236962	MYCOVIA PHARMS	Metalloenzyme inhibitor compounds	Apr, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754227	MYCOVIA PHARMS	Metalloenzyme inhibitor compounds	Apr, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 26, 2027
Generating Antibiotic Incentives Now(GAIN)	Apr 26, 2032

Drugs and Companies using OTESECONAZOLE ingredient

NCE-1 date: 27 April, 2031

Market Authorisation Date: 26 April, 2022

Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential

Dosage: CAPSULE;ORAL

VIVJOA family patents

205. Vosevi patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284342 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Mar, 2031 (6 years from now)
US8618076 (Pediatric)	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: 18 July, 2021

Market Authorisation Date: 18 July, 2017

Treatment: NA

Dosage: TABLET;ORAL

VOSEVI family patents

206. Wegovy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129343	NOVO	Acylated GLP-1 compounds	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 04, 2024
New Dosing Schedule(D-190)	Jul 21, 2026
New Indication(I-935)	Mar 08, 2027
New Patient Population(NPP)	Dec 23, 2025
New Chemical Entity Exclusivity(NCE)	Dec 05, 2022

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 04 June, 2021

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

WEGOVY family patents

207. Xadago patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283380	MDD US	Methods for treatment of parkinson's disease	Mar, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 21, 2022

Drugs and Companies using SAFINAMIDE MESYLATE ingredient

NCE-1 date: 21 March, 2021

Market Authorisation Date: 21 March, 2017

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes

Dosage: TABLET;ORAL

XADAGO family patents

208. Xenleta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9120727	NABRIVA	Process for the preparation of pleuromutilins	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 19, 2024
Generating Antibiotic Incentives Now(GAIN)	Aug 19, 2029

Drugs and Companies using LEFAMULIN ACETATE ingredient

NCE-1 date: 19 August, 2028

Market Authorisation Date: 19 August, 2019

Treatment: NA

Dosage: TABLET;ORAL

XENLETA family patents

209. Xermelo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8193204	TERSERA	Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use	Feb, 2031 (6 years from now)
US7709493	TERSERA	4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-132)	Feb 28, 2024
Orphan Drug Exclusivity(ODE)	Feb 28, 2024
New Chemical Entity Exclusivity(NCE)	Feb 28, 2022

Drugs and Companies using TELOTRISTAT ETIPRATE ingredient

NCE-1 date: 28 February, 2021

Market Authorisation Date: 28 February, 2017

Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy

Dosage: TABLET;ORAL

XERMELO family patents

210. Xhance patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10252010	OPTINOSE US INC	Nasal delivery devices	Feb, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 18, 2020

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: NA

Dosage: SPRAY, METERED;NASAL

XHANCE family patents

211. Xofluza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8987441	GENENTECH INC	Substituted polycyclic carbamoyl pyridone derivative prodrug	Sep, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927710	GENENTECH INC	Substituted polycyclic carbamoylpyridone derivative	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Oct 24, 2023
New Indication(I-811)	Oct 16, 2022

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: 24 October, 2022

Market Authorisation Date: 24 October, 2018

Treatment: NA

Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL

XOFLUZA family patents

212. Xospata patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969336	ASTELLAS	Diamino heterocyclic carboxamide compound	Jan, 2031 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-222)	Nov 28, 2025
New Chemical Entity Exclusivity(NCE)	Nov 28, 2023

Drugs and Companies using GILTERITINIB FUMARATE ingredient

NCE-1 date: 28 November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

XOSPATA family patents

213. Xtoro patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8536167	FONSECA BIOSCIENCES	Methods for treating ophthalmic, otic, or nasal infections	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 17, 2019
Pediatric Exclusivity(PED)	Jun 17, 2020

Drugs and Companies using FINAFLOXACIN ingredient

NCE-1 date: 18 June, 2019

Market Authorisation Date: 17 December, 2014

Treatment: Treatment of acute otitis externa

Dosage: SUSPENSION/DROPS;OTIC

XTORO family patents

214. Xyosted (autoinjector) patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10279131	ANTARES PHARMA INC	Injection device with cammed RAM assembly	Jul, 2031 (7 years from now)
US10905827	ANTARES PHARMA INC	Injection device with cammed ram assembly	Aug, 2031 (7 years from now)
US10357609	ANTARES PHARMA INC	Needle assisted jet injection device having reduced trigger force	Aug, 2031 (7 years from now)
US11446440	ANTARES PHARMA INC	Needle assisted injection device having reduced trigger force	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Sep 28, 2021

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

XYOSTED (AUTOINJECTOR) family patents

215. Yupelri patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8541451	MYLAN IRELAND LTD	Crystalline freebase forms of a biphenyl compound	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Nov 09, 2023

Drugs and Companies using REVEFENACIN ingredient

NCE-1 date: 09 November, 2022

Market Authorisation Date: 09 November, 2018

Treatment: NA

Dosage: SOLUTION;INHALATION

YUPELRI family patents

216. Zavzpret patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8481546	PFIZER	CGRP receptor antagonist	Oct, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 09, 2028

Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient

NCE-1 date: 10 March, 2027

Market Authorisation Date: 09 March, 2023

Treatment: Administration of zavegepant for acute treatment of migraine with or without aura

Dosage: SPRAY, METERED;NASAL

ZAVZPRET family patents

217. Zejula patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8071623	GLAXOSMITHKLINE	Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors	Mar, 2031 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859562	GLAXOSMITHKLINE	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	Aug, 2031 (7 years from now)

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 26 April, 2023

Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status

Dosage: TABLET;ORAL

ZEJULA family patents

218. Zemdri patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8383596	CIPLA USA	Antibacterial aminoglycoside analogs	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 25, 2023
Generating Antibiotic Incentives Now(GAIN)	Jun 25, 2028

Drugs and Companies using PLAZOMICIN SULFATE ingredient

NCE-1 date: 26 June, 2027

Market Authorisation Date: 25 June, 2018

Treatment: Method of using plazomicin to treat bacterial infections

Dosage: SOLUTION;INTRAVENOUS

ZEMDRI family patents

219. Zepatier patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8871759	MSD SUB MERCK	Inhibitors of hepatitis C virus replication	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Dec 09, 2024
New Chemical Entity Exclusivity(NCE)	Jan 28, 2021

Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient

NCE-1 date: 29 January, 2020

Market Authorisation Date: 28 January, 2016

Treatment: Treatment of patients infected with hepatitis c virus

Dosage: TABLET;ORAL

ZEPATIER family patents

220. Zepbound patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Feb, 2031 (6 years from now)
US9402957	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Jun, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 08, 2026
New Chemical Entity Exclusivity(NCE)	May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 March, 2024

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

ZEPBOUND family patents

221. Zilretta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828440	PACIRA PHARMS INC	Corticosteroids for the treatment of joint pain	Aug, 2031 (7 years from now)
US9555048	PACIRA PHARMS INC	Corticosteroids for the treatment of joint pain	Aug, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 06, 2020

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 06 October, 2017

Treatment: Method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

ZILRETTA family patents

222. Ztlido patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765640	SCILEX PHARMS	Non-aqueous patch	May, 2031 (7 years from now)
US11793766	SCILEX PHARMS	Non-aqueous patch for the relief of pain	May, 2031 (7 years from now)
US11278623	SCILEX PHARMS	Non-aqueous patch	May, 2031 (7 years from now)
US9925264	SCILEX PHARMS	Non-aqueous patch	May, 2031 (7 years from now)
US9283174	SCILEX PHARMS	Non-aqueous patch	May, 2031 (7 years from now)
US9931403	SCILEX PHARMS	Non-aqueous patch	May, 2031 (7 years from now)
US10765749	SCILEX PHARMS	Non-aqueous patch	May, 2031 (7 years from now)
US11786455	SCILEX PHARMS	Non-aqueous patch	May, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Feb 28, 2021

Drugs and Companies using LIDOCAINE ingredient

Market Authorisation Date: 28 February, 2018

Treatment: Method for relieving the pain associated with post-herpetic neuralgia

Dosage: PATCH;TOPICAL

ZTLIDO family patents

223. Zurampic patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216179	IRONWOOD PHARMS INC	Treatment of gout and hyperuricemia	Aug, 2031 (7 years from now)
US9956205	IRONWOOD PHARMS INC	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Dec 22, 2020

Drugs and Companies using LESINURAD ingredient

NCE-1 date: 23 December, 2019

Market Authorisation Date: 22 December, 2015

Treatment: Coadministering with allopurinol to reduce serum uric acid (sua) below 4 mg/dl; Below 6mg/dl in patients having uric acid deposits; And/or below 6mg/dl with sua intraday change more than 50% and/or ad...

Dosage: TABLET;ORAL

ZURAMPIC family patents

224. Zypitamag patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8829186	MEDICURE	Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof	Jan, 2031 (6 years from now)

Drugs and Companies using PITAVASTATIN MAGNESIUM ingredient

Market Authorisation Date: 14 July, 2017

Treatment: NA

Dosage: TABLET;ORAL

ZYPITAMAG family patents

List of large molecules

1. List of Avastin large molecules

Patent Number	Company	Patent Title	Patent Expiry
US8512983	GENENTECH, INC.	Production of proteins in glutamine-free cell culture media	Jan, 2031 (6 years from now)
US10011856	GENENTECH, INC.	Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase	May, 2031 (7 years from now)
US10662237	GENENTECH, INC.	Method to improve virus filtration capacity	May, 2031 (7 years from now)
US10704071	GENENTECH, INC.	Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase	Aug, 2031 (7 years from now)

Ingredients: BEVACIZUMAB

2. List of Tysabri large molecules

Patent Number	Company	Patent Title	Patent Expiry
US9096879	BIOGEN INC.	Method of supplementing culture media to prevent undesirable amino acid substitutions	Jan, 2031 (6 years from now)
US11287423	BIOGEN INC.	Assay for JC virus antibodies	Jan, 2031 (6 years from now)
US10444234	BIOGEN INC.	Assay for JC virus antibodies	Jan, 2031 (6 years from now)
US8318416	BIOGEN INC.	Nutrient monitoring and feedback control for increased bioproduct production	Jan, 2031 (6 years from now)
US8809049	BIOGEN INC.	Methods for producing mammalian cells	May, 2031 (7 years from now)
US9109015	BIOGEN INC.	Method of isolating biomacromolecules using low pH and divalent cations	Aug, 2031 (7 years from now)

Ingredients: NATALIZUMAB

3. List of Tremfya large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US7935344	NA	Human anti-IL-23 antibodies, compositions, methods and uses	Jan, 2031 (6 years from now)

Ingredients: GUSELKUMAB

4. List of Humira large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US8999337	ABBVIE INC.	Methods for treating juvenile idiopathic arthritis by inhibition of TNFα	Feb, 2031 (6 years from now)
US9624295	ABBVIE INC.	Uses and compositions for treatment of psoriatic arthritis	Mar, 2031 (6 years from now)

Ingredients: ADALIMUMAB

5. List of Siliq large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US7939070	NA	IL-17 receptor A antigen binding proteins	Feb, 2031 (6 years from now)

Ingredients: BRODALUMAB

6. List of Ilumya large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US8404813	NA	Engineered anti-IL-23P19 antibodies	Feb, 2031 (6 years from now)

Ingredients: TILDRAKIZUMAB-ASMN

7. List of Dupixent large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US7608693	NA	High affinity human antibodies to human IL-4 receptor	Mar, 2031 (6 years from now)

Ingredients: DUPILUMAB

8. List of Imfinzi large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US9493565	NA	Targeted binding agents against B7-H1	May, 2031 (7 years from now)

Ingredients: DURVALUMAB

9. List of Kevzara large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US7582298	NA	High affinity antibodies to human IL-6 receptor	Dec, 2031 (7 years from now)

Ingredients: SARILUMAB

Strength	Dosage	Availability
0.113MG/INH	POWDER;INHALATION	Prescription
0.03MG/INH	POWDER;INHALATION	Discontinued
0.232MG/INH	POWDER;INHALATION	Prescription
0.055MG/INH	POWDER;INHALATION	Prescription

Strength	Dosage	Availability
0.2MG/INH	POWDER;INHALATION	Prescription
0.05MG/INH	POWDER;INHALATION	Prescription
0.1MG/INH	POWDER;INHALATION	Prescription

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8524733	September, 2021	Terminated-Denied	Auspex Pharmaceuticals, Inc.	Apotex Inc.

Strength	Dosage	Availability
9MG	TABLET;ORAL	Prescription
12MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
12MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
24MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
6MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP17182561A	2019-11-26	Lederer & Keller Patentanwälte Partnerschaft mbB	Patent maintained as amended

Strength	Dosage	Availability
10MG/4ML (2.5MG/ML)	SOLUTION;INTRAVENOUS	Prescription
5MG/2ML (2.5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Dosage	Availability
EQ 300MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription
EQ 450MG BASE	TABLET;ORAL	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP11737745A	2017-07-05	isarpatent - Patent- und Rechtsanwälte Behnisch Barth Charles Hassa Peckmann und Partner mbB	Patent maintained as amended
EP11737745A	2017-07-05	Fresenius Kabi Deutschland GmbH	Patent maintained as amended
EP11737745A	2017-07-05	Wittkopp, Alexander	Patent maintained as amended
EP11737745A	2017-07-05	FRKelly	Patent maintained as amended

Application	Filing Date	Opposition Party	Legal Status

EP07864488A	2013-11-26	Sölch, Günter	Revoked
EP07864488A	2013-11-18	Zentiva k.s.	Revoked

Strength	Dosage	Availability
0.2MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription
0.1MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription
0.05MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

Strength	Dosage	Availability
0.4MG	CAPSULE;ORAL	Prescription
0.2MG	CAPSULE, PELLETS;ORAL	Prescription
0.6MG	CAPSULE, PELLETS;ORAL	Prescription
1.2MG	CAPSULE;ORAL	Prescription

Strength	Dosage	Availability
600MG/3ML (200MG/ML);900MG/3ML (300MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG/2ML (200MG/ML);600MG/2ML (300MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP11740764A	2022-07-13	Generics (U.K.) Limited	Granted and Under Opposition
EP11740764A	2022-07-12	STADA Arzneimittel AG	Granted and Under Opposition
EP11740764A	2022-07-12	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition

Strength	Dosage	Availability
EQ 60MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription
EQ 20MG BASE	TABLET;ORAL	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP16175117A	2020-05-14	Accord Healthcare Ltd	Granted and Under Opposition
EP16175117A	2020-05-14	Hetero Labs Limited	Granted and Under Opposition
EP16175117A	2020-05-13	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP10785289A	2015-02-27	SANDOZ AG	Patent maintained as amended

Application	Filing Date	Opposition Party	Legal Status

EP11833207A	2015-12-23	Fresenius Kabi Deutschland GmbH	Patent maintained as amended

Strength	Dosage	Availability
25MG/50ML (0.5MG/ML)	EMULSION;INTRAVENOUS	Prescription
50MG/100ML (0.5MG/ML)	EMULSION;INTRAVENOUS	Prescription
125MG/250ML (0.5MG/ML)	EMULSION;INTRAVENOUS	Discontinued

Strength	Dosage	Availability
EQ 25MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
20MG/ML (20MG/ML)	INJECTABLE;INJECTION	Prescription
160MG/8ML (20MG/ML)	INJECTABLE;INJECTION	Prescription
80MG/4ML (20MG/ML)	INJECTABLE;INJECTION	Prescription

Pharsight

Drug Patents Expiring in 2031

1. Abilify Mycite Kit patents expiration

ABILIFY MYCITE KIT family patents

2. Accrufer patents expiration

ACCRUFER family patents

3. Acetadote patents expiration

ACETADOTE family patents

4. Adlyxin patents expiration

ADLYXIN family patents

5. Afrezza patents expiration

AFREZZA family patents

6. Airduo Digihaler patents expiration

AIRDUO DIGIHALER family patents

7. Airduo Respiclick patents expiration

AIRDUO RESPICLICK family patents

8. Akeega patents expiration

AKEEGA family patents

9. Aklief patents expiration

AKLIEF family patents

10. Akynzeo patents expiration

AKYNZEO family patents

11. Alecensa patents expiration

ALECENSA family patents

12. Alunbrig patents expiration

ALUNBRIG family patents

13. Angeliq patents expiration

ANGELIQ family patents

14. Anoro Ellipta patents expiration

ANORO ELLIPTA family patents

15. Apadaz patents expiration

APADAZ family patents

16. Apretude patents expiration

APRETUDE family patents

17. Armonair Digihaler patents expiration

ARMONAIR DIGIHALER family patents

18. Armonair Respiclick patents expiration

ARMONAIR RESPICLICK family patents

19. Arnuity Ellipta patents expiration

ARNUITY ELLIPTA family patents

20. Aubagio patents expiration

AUBAGIO family patents

21. Austedo patents expiration

AUSTEDO family patents

22. Austedo Xr patents expiration

AUSTEDO XR family patents

23. Avycaz patents expiration

AVYCAZ family patents

24. Balversa patents expiration

BALVERSA family patents

25. Barhemsys patents expiration

BARHEMSYS family patents

26. Baxdela patents expiration

BAXDELA family patents

27. Belrapzo patents expiration

BELRAPZO family patents

28. Belviq patents expiration

BELVIQ family patents

29. Belviq Xr patents expiration

BELVIQ XR family patents

30. Bendeka patents expiration

BENDEKA family patents

31. Besivance patents expiration

BESIVANCE family patents

32. Bevespi Aerosphere patents expiration

BEVESPI AEROSPHERE family patents

33. Bevyxxa patents expiration

BEVYXXA family patents

34. Binosto patents expiration

BINOSTO family patents

35. Braftovi patents expiration

BRAFTOVI family patents

36. Brenzavvy patents expiration

BRENZAVVY family patents

37. Breo Ellipta patents expiration

BREO ELLIPTA family patents

38. Breztri Aerosphere patents expiration

BREZTRI AEROSPHERE family patents

39. Bryhali patents expiration

BRYHALI family patents

Application	Filing Date	Opposition Party	Legal Status

EP16187411A	2019-05-22	Sandoz AG	Granted and Under Opposition
EP16187411A	2019-05-22	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP16187411A	2019-05-22	STADA Arzneimittel AG	Granted and Under Opposition
EP16187411A	2019-05-20	Cooke, Richard	Granted and Under Opposition
EP15164931A	2018-12-21	Cooke, Richard	Granted and Under Opposition
EP15164931A	2018-12-19	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP11737484A	2016-02-05	LEK Pharmaceuticals d.d.	Revoked
EP11737484A	2016-02-05	Page White & Farrer Limited	Revoked
EP11737484A	2016-02-04	Ter Meer Steinmeister & Partner Patentanwälte mbB	Revoked
EP11737484A	2016-02-03	Teva Pharmaceutical Industries Ltd	Revoked

Application	Filing Date	Opposition Party	Legal Status

EP19209672A	2022-10-12	Luigi, Rumi	Granted and Under Opposition
EP19209672A	2022-10-12	Adalvo Ltd.	Granted and Under Opposition

Application	Filing Date	Opposition Party	Legal Status

EP11796324A	2018-12-21	Hexal AG	Revoked
EP11796324A	2018-12-21	Bülle Dr., Jan	Revoked
EP11796324A	2018-12-20	Alfred E. Tiefenbacher (GmbH & Co. KG)	Revoked
EP11853861A	2017-09-14	Alfred E. Tiefenbacher (GmbH & Co. KG)	Opposition rejected
EP11853861A	2017-09-14	STADA Arzneimittel AG	Opposition rejected

Strength	Dosage	Availability
300MG;200MG	TABLET;ORAL	Discontinued
200MG;200MG	TABLET;ORAL	Discontinued

Strength	Dosage	Availability
EQ 40MG MEDOXOMIL;25MG	TABLET;ORAL	Prescription
EQ 40MG MEDOXOMIL;12.5MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
10MG	TABLET;SUBLINGUAL	Prescription
5MG	TABLET;SUBLINGUAL	Prescription

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9326945	April, 2018	Terminated-Settled	Pfizer Inc.	Mylan Pharmaceuticals Inc.

Application	Filing Date	Opposition Party	Legal Status

EP11726055A	2015-09-28	Pentafarma Sociedade Técnico-Medicinal S.A.	Opposition rejected

Strength	Dosage	Availability
200MG;50MG/PACKET	PELLETS;ORAL	Prescription
400MG;100MG	TABLET;ORAL	Prescription
200MG;50MG	TABLET;ORAL	Prescription
150MG;37.5MG/PACKET	PELLETS;ORAL	Prescription

Strength	Dosage	Availability
EQ 40MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 120MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 80MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 20MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription